All Publications

 

[Square brackets indicate peer-reviewed publications]


Note that some reprints are available in pdf format by clicking on the linked number of the reprint.

         Furthermore, some of the references are linked to the publication source.


1.  ELIOT, C.R., KAJI, A., SEEMAN, P., UBELL, E., KUFFLER, S.W. and BURGEN, A.S.V.: 

The effect of nervous system extracts on inhibition and excitation to single nerve cells.  Biol.

Bull. 113: 344 (1957).


2. BURGEN, A.S.V. and SEEMAN, P.:  Partial equilibration in the ducts as a factor

determining saliva composition. Can. Physiol. Soc. Abstr. 20: 12 (1956).


3.[1]. BURGEN, A.S.V. and SEEMAN, P.:  The role of the salivary duct system in the formation

of the saliva.  Can. J. Biochem. Physiol. 36: 119-143 (1958).


4.[2]. SEEMAN, P. and O'BRIEN, E.:  Sodium-potassium-activated adenosine triphosphatase in

schizophrenic erythrocytes.  Nature 200: 263-264 (1963).


5. BURGEN, A.S.V. and SEEMAN, P.:  The interstitial diffusion of small molecules in the

salivary gland of the dog. 20th Int. Congr. Physiol. Abstr. (Brussels), 305 (1956).


6.[3]. SEEMAN, P. and BIALY, H.S.:  The surface activity of tranquilizers.  Biochem. Pharmacol.

12: 1181-1191 (1963).


7.[4].     BURGEN, A.S.V. and SEEMAN, P.:  The secretion of iodide in saliva. Can. J. Biochem.

Physiol. 35: 481-489 (1957).


8.[5]. SEEMAN, P.:  Erythrocyte membrane stabilization by steroids and alcohols:  A possible

model for anesthesia.  Biochem.  Pharmacol. 15: 1632-1637 (1966).


9.[6]. SEEMAN, P.:  A method for distinguishing specific from nonspecific hemolysins. Biochem.

Pharmacol. 15:  1767-1774 (1966).


10.[7]. SEEMAN, P.:  Erythrocyte membrane stabilization by local anesthetics and tranquilizers.

Biochem. Pharmacol. 15: 1753-1766 (1966).


11.[8].  SEEMAN, P., and WEINSTEIN, J.:  Erythrocyte membrane stabilization by tranquilizers and

anti-histamines.  Biochem. Pharmacol. 15: 1737-1752 (1966).


12.[9].   SEEMAN, P.:  Membrane stabilization by drugs: Tranquilizers, steroids and anesthetics.  Int.

Rev. Neurobiol. 9: 145-221 (1966).


13.[10].   SEEMAN, P.:  Transient holes in the erythrocyte membrane during hypotonic hemolysis and

stable holes in the membrane after lysis by saponin and lysolecithin.  J. Cell Biol. 32: 55-70

(1967).


14.[11].  SEEMAN, P., and PALADE, G.E.:  Acid phosphatase localization in rabbit eosinophils.  J.

Cell Biol. 34:  745-756 (1967).


15. SEEMAN, P.:  Subcellular membrane-drug interactions.  In:  The interaction of drugs and

subcellular components in animal cells, edited by P.N. Campbell , J. & A. Churchill Ltd.,

London, 212-213 (1968).


16.[12].  METCALFE, J., SEEMAN, P., and BURGEN, A.S.V.:  The proton relaxation of benzyl

alcohol in erythrocyte membranes. Mol. Pharmacol. 4: 87-95 (1968).


17.[13].   SEEMAN, P.:  Membrane stabilization and expansion by drugs.  In:  Metabolism and

membrane permeability of erythrocytes and thrombocytes, edited by E. Deutsch, E. Gerlach

and K. Moser, Georg Thieme Verlag, Stuttgart, 384-391 (1968).

 

1.  ELIOT, C.R., KAJI, A., SEEMAN, P., UBELL, E., KUFFLER, S.W. and BURGEN, A.S.V.: 

The effect of nervous system extracts on inhibition and excitation to single nerve cells.  Biol.

Bull. 113: 344 (1957).


2. BURGEN, A.S.V. and SEEMAN, P.:  Partial equilibration in the ducts as a factor

determining saliva composition. Can. Physiol. Soc. Abstr. 20: 12 (1956).


3.[1]. BURGEN, A.S.V. and SEEMAN, P.:  The role of the salivary duct system in the formation

of the saliva.  Can. J. Biochem. Physiol. 36: 119-143 (1958).


4.[2]. SEEMAN, P. and O'BRIEN, E.:  Sodium-potassium-activated adenosine triphosphatase in

schizophrenic erythrocytes.  Nature 200: 263-264 (1963).


5. BURGEN, A.S.V. and SEEMAN, P.:  The interstitial diffusion of small molecules in the

salivary gland of the dog. 20th Int. Congr. Physiol. Abstr. (Brussels), 305 (1956).


6.[3]. SEEMAN, P. and BIALY, H.S.:  The surface activity of tranquilizers.  Biochem. Pharmacol.

12: 1181-1191 (1963).


7.[4].     BURGEN, A.S.V. and SEEMAN, P.:  The secretion of iodide in saliva. Can. J. Biochem.

Physiol. 35: 481-489 (1957).


8.[5]. SEEMAN, P.:  Erythrocyte membrane stabilization by steroids and alcohols:  A possible

model for anesthesia.  Biochem.  Pharmacol. 15: 1632-1637 (1966).


9.[6]. SEEMAN, P.:  A method for distinguishing specific from nonspecific hemolysins. Biochem.

Pharmacol. 15:  1767-1774 (1966). 


10.[7]. SEEMAN, P.:  Erythrocyte membrane stabilization by local anesthetics and tranquilizers.

Biochem. Pharmacol. 15: 1753-1766 (1966).


11.[8].  SEEMAN, P., and WEINSTEIN, J.:  Erythrocyte membrane stabilization by tranquilizers and

anti-histamines.  Biochem. Pharmacol. 15: 1737-1752 (1966).


12.[9].   SEEMAN, P.:  Membrane stabilization by drugs: Tranquilizers, steroids and anesthetics.  Int.

Rev. Neurobiol. 9: 145-221 (1966).


13.[10].   SEEMAN, P.:  Transient holes in the erythrocyte membrane during hypotonic hemolysis and

stable holes in the membrane after lysis by saponin and lysolecithin.  J. Cell Biol. 32: 55-70

(1967).


14.[11].  SEEMAN, P., and PALADE, G.E.:  Acid phosphatase localization in rabbit eosinophils.  J.

Cell Biol. 34:  745-756 (1967).


15. SEEMAN, P.:  Subcellular membrane-drug interactions.  In:  The interaction of drugs and

subcellular components in animal cells, edited by P.N. Campbell , J. & A. Churchill Ltd.,

London, 212-213 (1968).


16.[12].  METCALFE, J., SEEMAN, P., and BURGEN, A.S.V.:  The proton relaxation of benzyl

alcohol in erythrocyte membranes. Mol. Pharmacol. 4: 87-95 (1968).


17.[13].   SEEMAN, P.:  Membrane stabilization and expansion by drugs.  In:  Metabolism and

membrane permeability of erythrocytes and thrombocytes, edited by E. Deutsch, E. Gerlach

and K. Moser, Georg Thieme Verlag, Stuttgart, 384-391 (1968).


18.[14]. SEEMAN, P.:  Membrane expansion and stabilization by anesthetics and other drugs.  In:

Permeability and function of biological membranes, edited by R.D. Keynes, W.R.

Loewenstein and B.A. Pethica, North-Holland, New York, 1970, pp. 40-56.


19.[15].  SEEMAN, P., SAUKS, T., ARGENT, W. and KWANT, W.:  The effect of membrane strain-

rate and of temperature on erythrocyte fragility and critical hemolytic volume. Biochim.

Biophys. Acta 183: 476-489 (1969). 


20.[16].  SEEMAN, P., KWANT, W.O., SAUKS, T. and ARGENT, W.:  Membrane expansion of

intact erythrocytes by anesthetics.  Biochim. Biophys. Acta 183: 490-498 (1969).


21.[17].  SEEMAN, P., KWANT, W.O. and SAUKS, T. :  Membrane expansion of erythrocyte ghosts

by tranquilizers and anesthetics. Biochim. Biophys. Acta 183: 499-511 (1969).


22.[18].  SEEMAN, P., and KWANT, W.O.:  Membrane expansion of the erythrocyte by both the

neutral and ionized forms of chlorpromazine.  Biochim. Biophys. Acta 183: 512-519 (1969).


23.[19].  SEEMAN, P.:  Temperature dependence of erythrocyte membrane expansion by alcohol

anesthetics.  Possible support for the partition theory of anesthesia.  Biochem. Biophys. Acta

183: 520-529 (1969).


24.[20].   KWANT, W.O., and SEEMAN, P.:  The membrane concentration of a local anesthetic

(chlorpromazine).  Biochim. Biophys. Acta 183: 530-543 (1969).


25. ROTH, S., and SEEMAN, P.:  The membrane concentration of anesthetics, and the

hydrophobic bond of the anesthetic-membrane interaction. Can. Fed. Biol. Soc. Abstr.12: 19

(1969).


26.   THORPE, W.R., and SEEMAN, P.:  Change in calcium binding of sarcolemma after

denervation. Can. Fed. Biol. Soc. Abstr. 13: 353 (1970).


27. CHAU, M., and SEEMAN, P.:  Membrane calcium is increased by anesthetics of low

molecular weight; a possible explanation for the anesthetic-induced sensitization of nerve and

muscle cells. Can. Fed. Biol. Soc. Abstr. 13: 433 (1970).


28. SEEMAN, P., and ROTH, S.:  Membrane expansion by anesthetics.  The hydrophobic nature

of the membrane-anesthetic bond.  4th Int. Congr. Pharmacol. Abstr. (Basel), 1969, p. 328,

Schwabe & Co., Basel. 


29. SEEMAN, P., CHAU, M., KWANT, W. and ROTH, S.:  The expansion and vesiculation of

membranes, and the displacement of membrane-bound calcium ions and ATP, by local

anesthetics. 3rd Int. Biophys. Congr. Abstr., 81 (1969).


30. SEEMAN, P., CHAU-WONG, M., SAUKS, T., GOLDBERG, M. and SAX, L.:  Membrane

calcium is increased by anesthetics of low molecular weight and decreased by adenosine

triphosphate; a possible explanation for the anesthetic-induced sensitization of nerve and

muscle cells.  Fed. Proc. 29: 548A (1970).


31.[21].  KWANT, W.O. and SEEMAN, P.:  The erythrocyte ghost is a perfect osmometer. J. Gen.

Physiol. 55: 208-219 (1970).


32. KWANT, W., ROTH, S. and SEEMAN, P.:  The binding of chlorpromazine and alcohol

anesthetics to membranes. Fed. Proc. 24: 614 (1969).


33.[22].  KWANT, W.O. and SEEMAN, P.:  The displacement of membrane calcium by a local

anesthetic (chlorpromazine).  Biochim. Biophys. Acta 193: 338-349 (1969).


34.[23].  BRAUN, W., ISHIZUKA, M. and SEEMAN, P.:  Suppression and enhancement of antibody

formation by alteration of Ca2+ levels.  Nature 226: 945-946 (1970).


35.[24].  SEEMAN, P.:  The membrane expansion theory of anesthesia.  In:  Molecular mechanisms of

anesthesia, edited by B.R. Fink, Raven Press, New York, 243-251 (1975).


36.[25].   MACLENNAN, D.H., SEEMAN, P., ILES, G.H. and YIP, C.C.:  Membrane formation by

the adenosine triphosphatase of sarcoplasmic reticulum. J. Biol. Chem. 246: 2702-2710

(1971).


37.[26].   SEEMAN, P., SHA'AFI, R., GALEY, W.R. and SOLOMON, A.K.:  The effect of anesthetics

(chlorpromazine, ethanol) on erythrocyte permeability to water. Biochim. Biophys. Acta 211:

365-368 (1970).


38.[27].   SEEMAN, P., ROTH, S. and SCHNEIDER, H.:  The membrane concentrations of alcohol

anesthetics.  Biochim. Biophys. Acta 225: 171-184 (1971).


39.[28].  SEEMAN, P., CHAU, M., GOLDBERG, M., SAUKS, T. and SAX, L.:  The binding of Ca2+

to the cell membrane increased by volatile anesthetics (alcohols, acetone, ether) which induce

sensitization of nerve or muscle.  Biochim. Biophys. Acta 225: 185-193 (1971).


40.[29].  KWANT, W.O. and SEEMAN, P.:  Chlorpromazine adsorption to brain regions.  Biochem.

Pharmacol. 20:  2089-2091 (1971).


41.[30].  THORPE, W.R. and SEEMAN, P.:  Effect of denervating skeletal muscle on calcium binding

by isolated sarcolemma.  Exp. Neurol. 30: 277-290 (1971).


42.[31]. SEEMAN, P.,:  Membrane anesthesia.  In:  Biological horizons in surface science, F. Sears

and L.M. Prince (Eds.), Academic Press, New York, 289-308 (1973).


43. SEEMAN, P. and ROTH, S.:  General anesthetics expand membranes at surgical

concentrations. Can. Fed. Biol. Soc. Abstr. 14: 132 (1971).


44.[32].  ROTH, S. and SEEMAN, P.:  All lipid-soluble anesthetics protect red cells.  Nature 231:

284-285 (1971).


45.[33].  SEEMAN, P., KWANT, W.O., GOLDBERG, M. and CHAU-WONG, M.: The effects of

ethanol and chlorpromazine on the passive membrane permeability to sodium ions.  Biochim.

Biophys. Acta 241: 349-355 (1971).


46. ROTH, S. and SEEMAN, P.:  General anesthetics expand membranes at surgical

concentrations. Int. Congr. Physiol. Sci. Abstr., Munich (1971).


47.[34].   CHAU-WONG, M. and SEEMAN, P.:  The control of membrane-bound calcium ions by

ATP.  Biochim.  Biophys. Acta 241: 473-482 (1971).


48.[35].  THORPE, W.R. and SEEMAN, P.:  The site of action of caffeine and procaine in skeletal

muscle. J. Pharmacol. Exp. Ther. 179: 324-330 (1971).


49. SEEMAN, P. and ROTH, S.:  General anesthetics expand membranes at surgical

concentrations.  The Pharmacologist 13: 270 (1971).


50.[36].  SEEMAN, P.:  The membrane actions of anesthetics and tranquilizers.  Pharmacol. Rev. 24:

583-655 (1972).


51.[37].  MACHLEIDT, H., ROTH, S. and SEEMAN, P.:  The hydrophobic expansion of erythrocyte

membranes by the phenol anesthetics.  Biochim. Biophys. Acta 255: 178-189 (1972).


52.[38].  SEEMAN, P. and ROTH, S.:  General anesthetics expand cell membranes at surgical

concentrations.  Biochim. Biophys. Acta 255: 171-177 (1972).


53.[39].   ROTH, S. and SEEMAN, P., AKERMAN, S.B.A. and CHAU-WONG, M.:  The action and

adsorption of local anesthetic enantiomers on erythrocyte and synaptosome membranes.

Biochim. Biophys. Acta 255: 199-206 (1972).


54.[40].   ROTH, S. and SEEMAN, P.: Anesthetics expand erythrocyte membranes without causing

loss of K+. Biochim. Biophys. Acta 255: 190-198 (1972).


55.[41]. ROTH, S. and SEEMAN, P.:  The membrane concentrations of neutral and positive

anesthetics (alcohol, chlorpromazine, morphine) fit the Meyer-Overton rule of anesthesia;

negative narcotics do not.  Biochim. Biophys. Acta 255: 207-219 (1972).


56.[42].   THORPE, W. and SEEMAN, P.:  Drug-induced contracture of muscle.  Int. Symp. on

Malignant Hyperthermia, edited by R.A. Gordon, B.A. Britt and W. Kalow, C.C. Thomas,

USA, 152-162 (1972).


57. ILES, G., SEEMAN, P., NAYLOR, D. and CINADER, B.:  Freeze-etch electron microscopy

of membrane holes produced by complement. Biophys. Soc. Abstr. 16: 259a (1972).


58.  SEEMAN, P.:  The membrane concentrations of general and local anesthetics fit the Meyer-

Overton-Mullins rule of anesthesia.  Fifth Int. Congr. Pharmacol. Abstr. 1239, p. 207 (1972).


59. SEEMAN, P., ILES, G., NAYLOR, D. and CINADER, B.:  Membrane ultrastructure of

complement- and anesthetic-induced lesions.  Can. Fed. Biol. Soc. Abstr. 15: 758 (1972).


60. ILES, G.H., COBBOLD, R.S.C. and SEEMAN, P.:  Technical aspects of the freeze-fracture

method of ultrastructure examination of cellular membranes.  Can.  Med. Biol. Eng. Soc. 4:

(1972).


61.[43].  MACLENNAN, D.H.,ILES, G.H., YIP, C.C. and SEEMAN, P.:  Isolation of sarcoplasmic

reticulum proteins.  Cold Spring Harbour Symp. 37: 469-477 (1973).


62.[44].   SEEMAN, P.: Membrane ultrastructure of complement-induced lesions.  In:  Recent physical

studies of the structure of biomembranes, edited by D. Chapman; and In:  Chem. Phys. Lipids

8: 270-277 (1972).


63.[45].   SEEMAN, P.:  Drug-induced expansion of biomembranes.  In:  Recent physical studies of

structure of biomembranes, edited by D. Chapman; and In:  Chem. Phys. Lipids 8: 361-365

(1972). 


64. SEEMAN, P.:  The membrane actions of the excitability-controlling drugs.  Neurosci. Soc.

Abstr. 2: 238 (1972).


65.[46].   THORPE, W.R. and SEEMAN, P.:  On the mechanism of the nicotine-induced contracture of

skeletal muscle. Can. J. Physiol. Pharmacol. 50: 920-923 (1972).


66.[47].   SEEMAN, P., CHAU-WONG, M. and MOYYEN, S.:  Membrane expansion by vinblastine

and strychnine.  Nature 241: 22 (1973).


67.[48].   SEEMAN, P.:  Macromolecules may inhibit diffusion of hemoglobin from lysing

erythrocytes by exclusion of solvent.  Can. J. Physiol. Pharmacol. 51: 226-229 (1973).



68.[49]. SEEMAN, P. and ILES, G.H.:  Pits in the freeze-cleavage plane of normal erythrocyte

membranes; and ultrastructure of membrane lesions in immune lysis.  Nouv. Rev. Fr.

d'Hematol. 12: 889-900 (1972).


69.[50].   SEEMAN, P., CHENG, D. and ILES, G.H.:  Structure of membrane holes in osmotic and

saponin hemolysis. J. Cell Biol. 56: 519-527 (1973).


70.[51].   ILES, G.H., SEEMAN, P., NAYLOR, D. and CINADER, B.:  Membrane lesions in immune

lysis: Surface rings, globule aggregates and transient openings.  J. Cell Biol. 56: 528-539

(1973).


71.[52].   SEEMAN, P., CHAU-WONG, M. and MOYYEN, S.:  Adsorption and conduction-block of

opiate narcotics on nerve membranes:  identical effects of levo- and dextro-forms. Can. J.

Physiol. Pharmacol. 50: 1181-1192 (1972).


72.[53].   SEEMAN, P., CHAU-WONG, M. and MOYYEN, S.:  Membrane binding of morphine,

diphenylhydantoin and tetrahydrocannabinol.  Can. J. Physiol. Pharmacol. 50: 1193-1200

(1972).


73.[54].   SEEMAN, P.:  The pH concept.  Science 177: 835-836 (1972). 


74. SEEMAN, P.:  The erythrocyte as a model for studying membrane stabilization by

tranquilizers, anesthetics, and steroids.  Diss. Abstr. 28 (No. 3), 1966, University Microfilms,

Ann Arbor.


75. SEEMAN, P., STAIMAN, A. and CHAU-WONG, M.:  Neurone-blocking actions of

antipsychotic drugs. Fed. Proc. 32: 248 (1973).


76.[55].   SEEMAN, P.:  The molecular basis of fluidity in membranes.  In: Recent physical studies of

structure of biomembranes, edited by D. Chapman, 1972, North-Holland, Amsterdam; and In:

Chem. Phys. Lipids 8: 311-313 (1972).


77.[56].   NAFTALIN, R.J., SEEMAN, P., SIMMONS, N.L. and SYMONS, M.C.R.:  A sugar-

dependent increase in red cell stability.  Biochim. Biophys. Acta 352: 146-171 (1974).


78. SEEMAN, P., STAIMAN, A. and CHAU-WONG, M.:  The neurone-blocking actions of

antipsychotic drugs.  Can. Fed. Biol. Soc. Abstr. 16: 7 (1973).


79.[57].   SEEMAN, P. :  Teach cH, not pH. Biochem. Educ. Quart. Bull. Int. Union Biochem. 1(3):

44-47 (1973). 


80.[58].   SEEMAN, P. and ILES, G.H.:  Pits in the freeze-cleavage plane of normal erythrocyte

membranes; and ultrastructure of membrane lesions in immune lysis.  In:  Red cell shape;

physiology, pathology, ultrastructure,  edited by M. Bessis, R.I. Weed and P.F. Leblond,

Springer-Verlag, New York, pp. 169-180, 1973.


81.[59].   SEEMAN, P., STAIMAN, A., LEE, T. and CHAU-WONG, M. :  The membrane actions of

tranquilizers in relation to neuroleptic-induced Parkinsonism and tardive dyskinesia.  Adv.

Biochem. Psychopharmacol. 9: 137-148 (1974).


82.[60].   SEEMAN, P., STAIMAN, A. and CHAU-WONG, M.:  The nerve impulse-blocking actions

of tranquilizers, and the binding of neuroleptics to synaptosome membranes. J. Pharmacol.

Exp. Ther. 190: 123-130 (1974).


83.[61].   SEEMAN, P. and LEE, T.:  The dopamine-releasing actions of neuroleptics and ethanol. J.

Pharmacol. Exp. Ther. 190: 131-140 (1974).


84.[62].   STAIMAN, A. and SEEMAN, P.: The impulse-blocking concentrations of anesthetics,

alcohols, anti-convulsants, barbiturates and narcotics on phrenic and sciatic nerves. Can. J.

Physiol. Pharmacol. 52: 535-550 (1974).


85.[63].   MULLER, P., SEEMAN, P. and SPERO, L. :  The additive effects of tranquilizers and

dopamine on smooth muscle. Can. J. Physiol. Pharmacol. 52: 551-557 (1974).


86.[64].   SEEMAN, P. and LEE, T.:  Enhanced binding of chlorpromazine to cholesterol-depleted

nerve membranes. Can. J. Physiol. Pharmacol. 52: 522-525 (1974).


87.[65].   SEEMAN, P., MACHLEIDT, H., KAHLING, J. and SENGUPTA, S.:  A new prolonged-

acting type of chlorpromazine:  Behavioural effects and prolonged actions on nerve

membranes.  Can. J. Physiol. Pharmacol. 52: 558-565 (1974).


88.[66].   SEEMAN, P., CHEN, S.S., CHAU-WONG, M. and STAIMAN, A.:  Calcium reversal of

nerve blockade by alcohols, anesthetics, tranquilizers and barbiturates. Can. J. Physiol.

Pharmacol. 52: 526-534 (1974).


90. SEEMAN, P.:  Comparison of presynaptic and postsynaptic theories of neuroleptic action. J.

Pharmacol. (Paris) 5, Suppl. 2:  91 (1974).


91. SEEMAN, P., WONG, M. and LEE, T.:  Dopamine receptor-block and nigral fiber-impulse

blockade by major tranquilizers. Fed. Proc. 33: 246, Abstr. 243 (1974).


92. STAIMAN, A., SPERO, L. and SEEMAN, P.:  Different sites of membrane action for

tetrodotoxin and lipid-soluble anesthetics.  Can. Fed. Biol. Soc. Abstr. 17: 160 (1974).


93. LEE, T. and SEEMAN, P.:  Tranquilizer-blockade of dopamine release from stimulated

striatal slices. Can. Fed. Biol. Soc. Abstr. 17: 57 (1974).


94. BARYSHNIK, S. and SEEMAN, P.:  Neuroleptic action on cholinergic transmission.  Can.

Fed. Biol. Soc. Abstr. 17: 57 (1974).


95. SEEMAN, P.:  Ultrastructure of membrane lesions in immune lysis, osmotic lysis and drug-

induced lysis. Fed. Proc. 33: 2116-2124 (1974).


96.[67].   SEEMAN, P.:  The membrane expansion theory of anesthesia:  Direct evidence using ethanol

and a high-precision density meter.  Experientia  30: 759-760 (1974).


97. SEEMAN, P. and LEE, T.:  Tranquilizer-blockade of dopamine release from stimulated

striatal slices. Soc. Neurosci. Abstr. 4: 418 (1974).


98.[68].   SEEMAN, P.: The actions of nervous system drugs on cell membranes. Hosp. Practice 9(9):

93-101 (1974).


99. PRCHAL, J.T., BLAKELY, J. and SEEMAN, P.:  Granulocyte-platelet Rosettes. Int. Congr.

Hematol. Abstr. (Jerusalem), 1974.


100.[69].  SEEMAN, P. and BROWN, G.M. (Editors):  Frontiers in Neurology and Neuroscience

Research 1974. First Int. Symp. Neurosci. Inst., Univ. of Toronto. Univ. of Toronto Press,

August, 1974, 154 pages.


101.[70]. SEEMAN, P. and LEE, T.:  Antipsychotic drugs:  Direct correlation between clinical potency

and presynaptic action on dopamine neurones.  Science 188: 1217-1219 (1975).


102.[71].  SEEMAN, P.:  Answers of an M.D. to questions of an M.P.  Can. Med. Assoc. J. 111: 707-

730 (1974).


103.[72].  MULLER, P. and SEEMAN, P.:  Neuroleptics:  Relation between cataleptic and anti-turning

actions, and role of the cholinergic system. J. Pharm. Pharmacol. 26: 981-984 (1974).


104.[73]. SEEMAN, P. and LEE, T.:  Neuroleptic drugs:  Direct correlation between clinical potency

and presynaptic action on dopamine neurons.  In: Antipsychotic drugs, pharmacodynamics

and pharmacokinetics, edited by G. Sedvall, Karolinska Institute, Pergamon Press Ltd.,

Oxford, pp. 183-191 (1976).


105. SEEMAN, P.:  Current advances in neuroscience and neurology research.  Univ. of Toronto

Med. J. 52: 47-48 (1975).


106.[74]. STAIMAN, A.L. and SEEMAN, P.:  Different sites of membrane action for tetrodotoxin and

lipid-soluble anesthetics.  Can. J. Physiol. Pharmacol. 53: 513-524 (1975).  


107. DONATI, F., KUNOV, H. and SEEMAN, P.:  Post-tetanic hyperpolarization in squid giant

axons.  Can. Fed. Biol. Soc. Abstr. 18: 104 (Abstr. 413) (1975).


108.[75]. SEEMAN, P.:  Action and interaction of psychoactive drugs on nerve impulse conduction

and release of neurotransmitters.  In:  Clinical pharmacology of psychoactive drugs, edited by

E.M.  Sellers, Alcoholism and Drug Addiction Research Foundation, Toronto, pp. 165-170

(1975).


109.[76]. SEEMAN, P. and SELLERS, E.M.:  Editors, Principles Of Medical Pharmacology. 1st

Edition,1975, 448 pages, University of Toronto Press.


110. SEEMAN, P., WONG, M. and TEDESCO, J. :  Tranquilizer receptors in rat striatum. Soc.

Neurosci. Abstr. 1: 405 (1975).


111. MULLER, P. and SEEMAN, P.:  Alterations in dopaminergic sensitivity in chronically

pretreated rats.  Soc. Neurosci. Abstr. 1: 412 (1975).


112. SEEMAN, P. and LEE, T.:  Antipsychotic drugs:  Direct correlation between clinical potency

and presynaptic actions on dopamine neurones.  6th Int. Congr. Pharmacol. Abstr. (1975).


113. SEEMAN, P.:  cH or pH.  Can. Med. Assoc. J. 112: 1384 (1975).


114.[77]. SEEMAN, P.:  The actions of nervous system drugs on cell membranes.  In: Cell membranes,

biochemistry, cell biology and pathology, edited by G. Weissmann and R. Claiborne, HP

Publ. Co., New York, N.Y. pp. 239-248 (1975).


115.[78]. SEEMAN, P., CHAU-WONG, M., TEDESCO, J. and WONG, K.:  Brain receptors for

antipsychotic drugs and dopamine:  Direct binding assays.  Proc. Nat. Acad. Sci., U.S.A. 72:

4376-4380 (1975).    


116. SEEMAN, P., LEE, T., CHAU-WONG, M. and WONG, K.:  Correlation of antipsychotic

drug potency and neuroleptic receptor block.  Soc. Neurosci. Abstr. 2: 878 (1976).


117. MULLER, P. and SEEMAN, P.:  Increased specific neuroleptic binding after chronic

haloperidol in rats.  Soc. Neurosci. Abstr. 2: 874 (1976).   


118.[79]. SEEMAN, P., LEE, T., CHAU-WONG, M. and WONG, K.: Antipsychotic drug doses and

neuroleptic/dopamine receptors. Nature 261: 717-719 (1976).


119.[80].  BROWN, G.M., SEEMAN, P. and LEE, T.:  Dopamine/neuroleptic receptors in basal

hypothalamus and pituitary.  Endocrinology 99: 1407-1410 (1976).


120.[81]. SEEMAN, P. and SELLERS, E.M.:  Editors, Principles Of Medical Pharmacology.  Second

Edition, 489 pages, University of Toronto Press, 1976.


121.[82]. EZRIN-WATERS, C., MULLER, P. and SEEMAN, P.: Catalepsy induced by morphine or

haloperidol:  Effects of apomorphine and anticholinergic drugs.  Can. J. Physiol. Pharmacol.

54: 516-519 (1976).


122.[83]. STAIMAN, A. and SEEMAN, P.:  Conduction-blocking concentrations of anesthetics

increase with nerve axon diameter:  Studies with alcohol, lidocaine and tetrodotoxin on single

myelinated fibers.  J. Pharmacol. Exp. Ther. 201: 340-349 (1977).


123.[84]. SEEMAN, P., LEE, T., CHAU-WONG, M., TEDESCO, J. and WONG, K.:  Dopamine

receptors in human and calf brains, using 3H-apomorphine and an antipsychotic drug.  Proc.

Nat. Acad. Sci. U.S.A. 73: 4354-4358 (1976).


124.[85]. EZRIN-WATERS, C. and SEEMAN, P.:  Tolerance to haloperidol catalepsy.  Eur. J.

Pharmacol. 41: 321-327 (1977).


125.[86]. SEEMAN, P.: Anti-schizophrenic drugs: Membrane receptor sites of action. Biochem.

Pharmacol. 26:  1741-1748 (1977).


126.[87]. CURRAN, M. and SEEMAN, P.:  Alcohol tolerance in a cholinergic nerve terminal. Relation

to the membrane expansion-fluidization theory of ethanol action.  Science 197: 910-911

(1977).


127.[88]. SEEMAN, P.: Anesthetics and pressure reversal of anesthesia:  Expansion and recompression

of membrane proteins, lipids and water.  Anesthesiology 47: 1-3 (1977). (Invited Editorial

Review).


128.[89]. WHITAKER, P.M. and SEEMAN, P.:  Hallucinogen binding to dopamine/neuroleptic

receptors. J. Pharm. Pharmacol. 29: 506-507 (1977).


129.[90]. FRIEND, W.C., BROWN, G.M., JAWAHIR, G., LEE, T. and SEEMAN, P.: Effect of

haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum.

Amer. J. Psychiat. 135: 839-841 (1978).


130.[91]. SEEMAN, P.:  Brain chemistry, schizophrenia and major tranquilizers.  Health Research

Ontario. Ministry of Health, Government of Ontario, Toronto, pp. 115-124 (1977).


131.[92]. SEEMAN, P., TEDESCO, J.L., LEE, T., CHAU-WONG, M., MULLER, P., BOWLES, J.,

WHITAKER, P.M., McMANUS, C., TITTLER, M., WEINREICH, P., FRIEND, W.C. and

BROWN, G.M.: Dopamine receptors in the central nervous system.  Fed. Proc. 37: 130-136

(1978).


132. LEE, T. and SEEMAN, P.:  Dopamine receptors in human and calf brains. Soc. Biol.

Psychiat. Abstr. (Toronto meeting),  1977.


133. TEDESCO, J.L., BOWLES, J., McDERMED, J.D. and SEEMAN, P.:  Conformational

requirements for the 3H-apomorphine receptor: Stereospecific binding of 2-aminotetralin

derivatives. Soc. Neurosci. Abstr. 3: 462 (1977).


134. TITTLER, M., WEINREICH, P. and SEEMAN, P.:  Brain dopamine receptor binding of 3H-

dihydroergo-cryptine.  Soc. Neurosci. Abstr. 3: 440 (1977).


135. EZRIN-WATERS, C. and SEEMAN, P.:  Effect of chronic L-DOPA on apomorphine-

induced rotation and sniffing in rats.  Soc. Neuosci. Abstr. 3: 464 (1977).


136. WHITAKER, P.M. and SEEMAN, P.:  Overlap of dopamine- and serotonin-displaceable

LSD binding in cow caudate. Soc. Neurosci. Abstr. 3: 461 (1977).


137. LEE, T. and SEEMAN, P.:  Dopamine receptors in normal and schizophrenic human brains. 

Soc. Neurosci. Abstr. 3: 443 (1977).


138. MULLER, P., BOWLES, J. and SEEMAN, P.: Dopaminergic and cholinergic receptors in

striatal and limbic regions after chronic haloperidol. Soc. Neurosci. Abstr. 3: 459 (1977).


139. BROWN, G.M., PORIETIS, A., SEEMAN, P., FRIEND, W.C. and LEE, T.: Dopamine

immuno-histology and neuroleptic/dopamine receptors in the striatum and the pituitary.  22nd

Annual Psychiatric Res. Meeting,  Saskatchewan, Canada (1977).


140.[93]. SEEMAN, P., TITTLER, M., TEDESCO, J. and LEE, T.:  Neuroleptic sites of membrane

action:  Nonspecific (anesthetic) and specific (dopamine receptors).  In: Biological  Activity

and Chemical Structure.  Int. Symp. IUPHAR-IUPAC Medicinal Chem series, The

Netherlands, Elsevier Publ. Co., pp. 131-145 (1977).


141.[94]. EZRIN-WATERS, C. and SEEMAN, P.:  Haloperidol-induced tolerance to morphine

catalepsy.  Life Sci. 21:  419-422 (1977).


142.[95]. SEEMAN, P., TITELER, M., TEDESCO, J., WEINREICH, P. and SINCLAIR, D.: Brain

receptors for dopamine and neuroleptics.  Adv. Biochem. Psychopharmacol. 19: 167-176

(1978).


143.[96]. TITTLER, M., WEINREICH, P. and SEEMAN, P.:  New detection of brain dopamine

receptors with 3H-dihydroergocryptine.  Proc. Nat. Acad. Sci., U.S.A. 74: 3750-3753 (1977).


144.[97]. MULLER, P. and SEEMAN, P.:  Effect of long-term neuroleptic treatment on

neurotransmitter receptors:  Relation to tardive dyskinesia.  In:  Tardive dyskinesia, edited by

J.M. Davis, W.E. Fann, E. Domino and R.C. Smith, Spectrum John Wiley Press, New York

(1977), pp. 405-410.


145.[98]. MULLER, P. and SEEMAN, P.:  Brain neurotransmitter receptors after long-term

haloperidol: Dopamine, acetylcholine, serotonin, alpha-adrenergic and naloxone receptors.

Life Sci. 21: 1751-1758 (1977).


146.[99]. LEE, T., SEEMAN, P., TOURTELLOTTE, W.W., FARLEY, I.J. and HORNYKIEWICZ,

O.: Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.  Nature 274:

897-900 (1978).


147.[100]. LEE, T., SEEMAN, P., RAJPUT, A., FARLEY, I.J. and HORNYKIEWICZ, O.:  Receptor

basis for dopaminergic supersensitivity in Parkinson's disease.  Nature 273: 59-61 (1978).


148.[101]. NAGY, J.I., LEE, T., SEEMAN, P. and FIBIGER, H.C.:  Direct evidence for presynaptic and

postsynaptic dopamine receptors in brain.  Nature 274: 278-281 (1978).


149.[102]. EZRIN-WATERS, C. and SEEMAN, P.:  L-DOPA reversal of hyperdopaminergic

behaviour.  Life Sci. 22:  1027-1032 (1978).


150.[103]. TITELER, M., WEINREICH, P., SINCLAIR, D. and SEEMAN, P.:  Multiple receptors for

brain dopamine. Proc. Nat. Acad. Sci., U.S.A. 75: 1153-1156 (1978).


151.[104]. WHITAKER, P.M. and SEEMAN, P.:  Selective labeling of serotonin receptors by 3H-LSD

in calf caudate. Proc. Nat. Acad. Sci. U.S.A. 75: 5783-5787 (1978).


152.[105]. McMANUS, C., HARTLEY, E.J. and SEEMAN, P.: Increased binding of 3H-apomorphine in

caudate membranes after dopamine pretreatment in vitro.  J. Pharm. Pharmacol. 30: 444-447

(1978).


153.[106]. MULLER, P. and SEEMAN, P.:  Dopaminergic supersensitivity after neuroleptics: Time-

course and specificity.  Psychopharmacology 60: 1-11 (1978).


154. SEEMAN, P.:  On "Essays in neurochemistry and Neuropharmacology", Vol. 1, edited by

M.B.H. Youdim, D.F. Sharman, W. Lovenberg and J.R. Lagnado, In:  J. Med. Chem. 20:

1537-1538 (1977).


155. LEE, T., SEEMAN, P., RAJPUT, A., FARLEY, I. and HORNYKIEWICZ, O.:  Parkinson's

disease:  Brain dopamine receptors.  Fed. Proc. 37:  382 (1978).


156.[107]. MULLER, P., BRITTON, R.S. and SEEMAN, P.:  The effects of long-term ethanol on brain

receptors for dopamine, acetylcholine, serotonin and noradrenaline. Eur. J. Pharmacol. 65: 31-

37 (1980).


157.[108]. TITELER, M. and SEEMAN, P.:  Selective labeling of alpha-adrenergic receptors in caudate

nucleus by 3H-dihydroergocryptine in the presence of spiperone-blocked dopamine receptors. 

Proc. Nat. Acad. Sci., U.S.A. 75: 2249-2253 (1978).


158.[109]. SEEMAN, P., TEDESCO, J., TITELER, M., and HARTLEY, E.J.:  Anti-schizophrenic

drugs: Membrane receptor sites of action.  In: Neuropsychopharmacology, edited by C.

Dumont, Adv. Pharmacol. Ther. 5:  3-20, Pergamon Press, Oxford, 1978.


159.[110]. TITELER, M., TEDESCO, J.L. and SEEMAN, P.: Selective labeling of presynaptic receptors

by 3H-dopamine, 3H-apomorphine and 3H-clonidine; labeling of postsynaptic sites by 3H-

neuroleptics. Life Sci. 23:  587-592 (1978).


160.[111]. HARTLEY, E.J. and SEEMAN, P.: The effect of varying 3H-spiperone concentration on its

binding parameters.  Life Sci. 23: 513-518 (1978).


161. SEEMAN, P., LEE, T., HORNYKIEWICZ, O., FARLEY, I., BIRD, E., TOURTELLOTTE,

W.W. and SPOKES, E.M.:  Schizophrenia:  Increased neuroleptic binding in dopamine-rich

regions of human brains.  11th Colleg. Int. Neuropsychopharmacol. Abstr. (1978) p. 215.


162.[112]. CURRAN, M. and SEEMAN, P.:  Mechanisms of ethanol tolerance at a cholinergic nerve

terminal. Drug and Alcohol Dependence 4: 167-172 (1978).


163.[113]. DIRENFELD, L., SPERO, L., MAROTTA, J. and SEEMAN, P.:  The L-DOPA on-off effect

in Parkinson disease:  Treatment by transient drug withdrawal and dopamine receptor

resensitization.  Annals Neurol. 4: 573-575 (1978).


164.[114]. TITELER, M. and SEEMAN, P.:  Antiparkinsonian drug doses and neuroleptic receptors.

Experientia 34:  1491-1492 (1978).


166.[115]. MULLER, P. and SEEMAN, P.:  Presynaptic subsensitivity as a possible basis of

dopaminergic sensitization by long-term dopamine-mimetics.  Eur. J. Pharmacol. 55: 149-157

(1979).


167.[116]. TEDESCO, J.L., SEEMAN, P. and McDERMED, J.D.:  The conformation of dopamine at its

receptor:  Binding of monohydroxy-2-aminotetralin enantiomers and positional isomers. Mol.

Pharmacol. 16: 369-381 (1979).


168. WHITAKER, P.M. and SEEMAN, P.:  Selective labelling of serotonin receptors by 3H-LSD.

Soc. Neurosci. Abstr. 4: 526 (1978).


169. TITELER, M. and SEEMAN, P.:  Pre- and post-synaptic catecholamine receptors in calf

caudate. Soc. Neurosci. Abstr. 4: 523 (1978).


170. SEEMAN, P. and TEDESCO, J.:  Presynaptic dopamine receptors labelled by 3H-

apomorphine.  Soc. Neurosci. Abstr. 4: 521 (1978).


170A. TEDESCO, J.L. and SEEMAN, P.: Pre-synaptic dopamine receptor binding:  Involvement of

the nitrogen lone electron pair.  Soc. Neurosci. Abstr. 4: 522 (1978).


171. LEE, T. and SEEMAN, P.:  Enhanced 3H-neuroleptic binding in post-mortem schizophrenic

brains. Soc. Neurosci. Abstr. 4: 496 (1978).


172. WEINREICH, P., LEE, T. and SEEMAN, P.:  Striatal interdependence and pre- and post-

synaptic dopamine receptors.  Soc. Neurosci.  Abstr. 4: 524 (1978).


173.[117]. TITELER, M., SEEMAN, P. and HENN, F.: Differential centrifugation of 3H-apomorphine

and 3H-spiro-peridol binding sites.  Eur. J. Pharmacol. 51: 459-460 (1978).


174.[118]. SEEMAN, P., WOODRUFF, G.N. and POAT, J.:  Similar binding of 3H-ADTN and 3H-

apomorphine to calf brain dopamine receptors.  Eur. J. Pharmacol. 55:  137-142 (1979).


175.[119]. TAM, S. and SEEMAN, P.: Neuroleptic receptors in calf caudate: Solubilization by

digitonin. Eur. J. Phamacol. 52: 151-152 (1978).


176.[120]. EZRIN-WATERS, C., SEEMAN, M.V. and SEEMAN, P.:  Tardive dyskinesia in

schizophrenic outpatients:  Prevalence and significant variables. J. Clin. Psychiat. 42: 16-22

(1981).


177.[121]. SEEMAN, P., WESTMAN, K., PROTIVA, M., JILEK, J., JAIN, P.C., SAXENA, A.K.,

ANAND, N., HUMBER, L. and PHILIPP, A.: Neuroleptic receptors: Stereoselectivity for

neuroleptic enantiomers. Eur. J. Pharmacol. 56: 247-251 (1979).


178.[122]. LIST, S. and SEEMAN, P.: Dopamine agonists reverse the elevated 3H-neuroleptic binding

in neuroleptic-pretreated rats. Life Sci. 24: 1447-1452 (1979).


179.[123]. WHITAKER, P.M. and SEEMAN, P.: High affinity 3H-serotonin binding to caudate:

Inhibition  by hallucinogens and serotonergic drugs. Psychopharmacology 59: 1-5 (1978).


180. SEEMAN, P., LEE, T., HORNYKIEWICZ, O., FARLEY, I., BIRD, E., TOURTELLOTTE,

W.W., and SPOKES, E.M.:  Schizophrenia:  Increased neuroleptic binding in dopamine-rich

regions of human brain.  11th Colleg. Int.. Neuropsychopharmacologicum Abstr. [Vienna] p.

215, (1978).


181.[124]. HARTLEY, E.J., SPUHLER, K., PRASAD, K.N. and SEEMAN, P.:  A neuroblastoma clone

which has dopamine-sensitive adenylate cyclase but which lacks stereospecific binding site

for the neuroleptic 3H-spiperone.  Brain Res. 190: 574-577 (1980).


182.[125]. WHITAKER, P.M. and SEEMAN, P.:  Selective labeling of apomorphine receptors by 3H-

LSD. Eur. J. Pharmacol. 56: 269-271 (1979).


183. SEEMAN, P., LEE, T., BIRD, E.D., SPOKES, E.M., TOURTELLOTTE, W.W., FARLEY,

I. and HORNYKIEWICZ, O.: Neuroleptic receptors in post-mortem schizophrenic brains.

11th Colleg. Internat. Neuropsychopharmacologicum Abstr. (Vienna):  p. 307 (1978).


184.[126]. TITELER, M. and SEEMAN, P.:  Ergot and catecholamine potencies at catecholamine

receptors.  In:  Ergot compounds and brain function:  Neuroendocrine and neuropsychiatric

aspects.  Adv. Biochem. Psychopharmacol. 23: 35-40 (1980).


185.[127]. SEEMAN, P., LEE, T., BIRD, E.D. and TOURTELLOTTE, W.W.:  Elevation of brain

neuroleptic/dopamine receptors in schizophrenia. In: Perspectives in schizophrenia research,

edited by C. Baxter and T. Melnechuk, Raven Press, New York, 1980, pp. 195-202.


186.[128]. LIST, S. and SEEMAN, P.:  Neuroleptic/dopamine receptors; elevation and reversal.  In:

Long-term effects of neuroleptics.  Adv. Biochem. Psychopharmacol. 24: 95-101 (1980).


187.[129]. LEE, T. and SEEMAN, P.:  Elevation of brain neuroleptic/dopamine receptors in

schizophrenia. Amer. J. Psychiat. 137: 191-197 (1980).


188.[130]. DIRENFELD, L., SPERO, L., MAROTTA, J. and SEEMAN, P.:  Chronic agonist-induced

hypersensitivity and on-off hyperkinesis; Reply.  Annals Neurol. 6: 277-279 (1979).


189.[131]. WEINREICH, P. and SEEMAN, P.:  Effect of kainic acid on striatal dopamine receptors.

Brain Res. 198:  491-496 (1980).


190.[132]. SEEMAN, P., WESTMAN, K., COSCINA, D. and WARSH, J.J.:  Serotonin receptors in

hippocampus and frontal cortex.  Eur. J. Pharmacol. 66: 179-191 (1980).


191.   TANG, S.W. and SEEMAN, P.:  Effect of antidepressants on noradrenergic and serotonergic

receptors.  Soc. Neurosci. Abstr. 5: 353 (1979).


192.[133]. TITELER, M. and SEEMAN, P.:  In vitro measurement of brain receptors for dopamine and

neuroleptics.  In:  The neurobiology of dopamine, edited by A.S. Horn, B.H.C. Westerink and

J. Korf, Academic Press (1979), p. 179-195.


193. EZRIN-WATERS, C., SEEMAN, M.V. and SEEMAN, P.:  Prevalence of tardive dyskinesia

in schizophrenic outpatients. Roy. Coll. Phys. (Canada) Abstr., Montreal, 1979.


194.[134]. SEEMAN, P.:  Brain chemistry, schizophrenia and major tranquilizers.  Ontario Health Res.

Newslett. 1 (No. 2):  1-3 (1979).


195.[135]. TITELER, M. and SEEMAN, P.:  Selective labeling of different dopamine receptors by a

new agonist 3H-ligand:  3H-N-propylnorapomorphine.  Eur. J. Pharmacol. 56: 291-292 (1979).


196.[136]. TITELER, M. and SEEMAN, P.:  Radioreceptor labeling of pre- and post-synaptic dopamine

receptors.  In:  Long-term effects of neuroleptics.  Adv. Biochem. Psychopharmacol. 24: 159-

165 (1980).


197. TANG, S.W. and SEEMAN, P.:  The noradrenergic and serotonergic properties of

antidepressants.  Can. Psychiat. Assn. Abstr. (Vancouver, Sept. 1979).


198. LIST, S., TITELER, M. and SEEMAN, P.: Properties of high affinity 3H-dopamine binding

sites in rat striatum. Soc. Neurosci. Abstr. 5: 654 (1979).


199. WEINREICH, P., TITELER, M. and SEEMAN, P.:  Identification of 3H-clonidine binding

sites in rat brain. Soc. Neurosci. Abstr. 5: 576 (1979).


200. TITELER, M. and SEEMAN, P.:  Agonist potencies at the dopamine receptor.  Soc.

Neurosci. Abstr. 5: 664 (1979).


201. LEE, T. and SEEMAN, P.:  Correlation of antipsychotic drug potency and neuroleptic

receptor inhibition of post-mortem human brains. Soc. Neurosci. Abstr. 5: 653 (1979).


202.[137]. LEE, T. and SEEMAN, P.: Abnormal neuroleptic/dopamine receptors in schizophrenia.  Adv.

Biochem. Psychopharmacol. 21: 435-442 (1980).


203.[138]. SEEMAN, P., SELLERS, E.M. and ROSCHLAU, W.H.E.:  Editors, Principles of Medical

Pharmacology. Third Edition, 690 pages, 1980.


204.[139]. TITELER, M., LIST, S. and SEEMAN, P.: High-affinity dopamine receptors (D3) in rat

brain. Communic. Psychopharmacol. 3: 411-420 (1979).


205.[140]. TANG, S.W. and SEEMAN, P.: Effect of antidepressant drugs on serotonergic and

adrenergic receptors.  Naunyn-Schmied. Arch. Pharmacol. 311: 255-261 (1980).


206.[141]. LIST, S., TITELER, M. and SEEMAN, P.:  High-affinity 3H-dopamine receptors (D3 sites) in

human and rat brain. Biochem. Pharmacol. 29: 1621-1622 (1980).


207.[142]. WEINREICH, P., DECK, J. and SEEMAN, P.:  Multiple binding sites in human brain for 3H-

clonidine and 3H-WB-4101.  Biochem. Pharmacol. 29: 1869-1870 (1980).


208.[143]. TITELER, M. and SEEMAN, P.: Presynaptically acting catecholamines bind to alpha2-

adrenoceptors labelled by 3H-clonidine. Eur. J. Pharmacol. 67: 187-192 (1980).


209.[144]. FIRNAU, G., GARNETT, S., MARSHALL, A.M., SEEMAN, P., TEDESCO, J. and KIRK,

K.L.: Effects of fluoro-dopamines on dopamine receptors (D1, D2, D3 sites).  Biochem.

Pharmacol. 30: 2927-2930 (1980).


210. SEEMAN, P. and LEE, T.: Brain dopamine receptors (D2 and D3 sites) in Parkinson's disease

and schizophrenia.  12th Colleg. Int. Neuropsychopharmacologicum Abstr. (Goteborg), Progr.

Neuropsychopharma-col. 4, Suppl., 1980, Abstr. 609, p. 317.


211. SEEMAN, P.:  Receptor research in psychopharmacology:  Past and future. 12th Int. Colleg.

Neuropsycho-pharmacologicum Abstr. (Goteborg); Progr. Neuropsychopharmacol. 4, Suppl.,

p.317, 1980.


212. LEE, T. and SEEMAN, P.:  Dopamine receptor binding in schizophrenia and Parkinson's

disease. 12th Int. Colleg. Neuropsychopharmacologicum Abstr. (Goteborg); Progr.

Neuropsychopharmacol. 4, Suppl., 1980, Abstr. 391, p. 221.


213. SEEMAN, P.:  Brain dopamine receptors in schizophrenia.  12th Int. Colleg.

Neuropsychopharmacologicum Abstr. (Goteborg); Progr. Neuropsychopharmacol. 4, Suppl.,

1980, p. 318.


214.[145]. MADRAS, B., DAVIS, A., KUNASHKO, P. and SEEMAN, P.:  Solubilization of dopamine

receptors from human and dog brain.  In:  Psychopharmacology and biochemistry of neurotransmitter receptors, edited by H. Yamamura, R. Olsen and E. Usdin,Elsevier North

Holland, New York, pp. 411-419, 1980.


215.[146]. LIST, S. and SEEMAN, P.: Dopamine receptors in human brain:  comparison with rat and

calf brain.  In:  Transmitter biochemistry of human brain tissue, edited by E. Usdin and P.

Riederer, Macmillan, London, pp. 195-202, 1980.


216.[147]. HELMESTE, D.M., SEEMAN, P.and COSCINA, D.V.: Relation between brain

catecholamine receptors and dopaminergic stereotypy in rat strains.  Eur. J. Pharmacol. 69:

465-470 (1981).


217. TANG, S.W., SEEMAN, P. and KWAN, S.: Effect of chronic tricyclic antidepressant

treatment on serotonergic and histaminergic receptors. Soc. Neurosci. Abstr. 6: 861 (1980).


218. LIST, S. and SEEMAN, P.: High-affinity 3H-dopamine receptors in human brain. Soc.

Neurosci. Abstr. 6: 240 (1980).


219. MADRAS, B.K., DAVIS, A. and SEEMAN, P.: Solubilization of the neuroleptic/dopamine

(D2) receptor from dog striatum. Soc. Neurosci. Abstr. 6: 240 (1980).


220. HELMESTE, D.M., SEEMAN, P. and COSCINA, D,V.: Genetic differences in

catecholamine receptors and dopamine-mediated behaviour in rats. Soc. Neurosci. Abstr.  6: 3

(1980).


221. DAVIS, A., MADRAS, B.K. and SEEMAN, P.: Solubilization of the neuroleptic binding site

of human brain.  Soc. Neurosci. Abstr. 6: 500 (1980).


222. LEE, T. and SEEMAN, P.: Dopamine receptors in schizophrenic human brains: differential

changes. Soc. Neurosci. Abstr. 6: 600 (1980).


223.[148]. SEEMAN, P.:  Current biochemical research (on schizophrenia). Montage (Clarke Institute)

5(2): 1-4 (1979).


224.[149]. SEEMAN, P.: Dopamine and schizophrenia. Can. Psychiat. Assoc. Bull. Sept. 9-1 (1979).


225.[150]. DUMBRILLE-ROSS, A., TANG, S.W. and SEEMAN, P.: High-affinity binding of 3H-

mianserin to rat cerebral cortex. Eur. J. Pharmacol. 68: 395-396 (1980).


226.[151]. LEE, T., SEEMAN, P., HORNYKIEWICZ, O., BILBAO, J., DECK, J. and

TOURTELLOTTE, W.: Parkinson's disease: Low density and presynaptic location of D3

dopamine receptor sites. Brain Res. 212: 494-498 (1981).


227.[152]. DAVIS, A., MADRAS, B. and SEEMAN, P.: Solubilization of neuroleptic/dopamine

receptors of human brain striatum. Eur. J. Pharmacol. 70: 321-329 (1981).


228.[153]. LIST, S.J. and SEEMAN, P.: Resolution of the dopamine and serotonin receptor components

of 3H-spiperone binding to rat brain regions. Proc. Nat. Acad. Sci., U.S.A. 78: 2620-2624

(1981).


229.[154]. WEINREICH, P., CHIU, A., WARSH, J. and SEEMAN, P.: Multiple binding sites for 3H-

clonidine and 3H-WB-4101 in rat brain. Canad. J. Physiol. Pharmacol. 59: 1170-1177 (1981).


230.[155]. TANG, S.W., SEEMAN, P. and KWAN, S.: Differential effect of chronic desipramine and

amitriptyline treatment on rat brain adrenergic and serotonergic receptors. Psychiat. Res. 4:

129-138 (1981).


231.[156]. DAVIS, A., MADRAS, B.K. and SEEMAN, P.: Solubilized receptors for 3H-dopamine (D3

binding sites) from canine brain. Biochem. Pharmacol. 31: 1183-1187 (1982).


232.[157]. WEINREICH, P. and SEEMAN, P.: Binding of adrenergic ligands ([3H]clonidine and

[3H]WB-4101) to multiple sites in human brain. Biochem. Pharmacol. 30: 3115-3120 (1981).


233.[158]. TITELER, M., VAN LOON, G.R., SEEMAN, P. and BROWN, G.M.:  D2 but no D3

dopamine receptors detected in the anterior pituitary.   Eur. J. Pharmacol. 71: 143-146 (1981).


234.[159]. LEE, T. and SEEMAN, P.:  Brain dopamine receptors in schizophrenia.  In:  Biological

markers in psychiatry and neurology, E. Usdin and I. Hanin (Eds.), Pergamon Press, New

York, pp. 219-226, 1982.


235.[160]. SEEMAN, P., TITELER, M. and LIST, S.:  Dopamine receptors in brain and pituitary.  In:

Brain peptides and hormones, edited by R. Collu, J.R. Ducharme, A. Barbeau and G. Tolis,

Raven Press, New York, pp. 31-42, 1982.


236.[161]. CHAN, B., MADRAS, B.K., DAVIS, A. and SEEMAN, P.: Assay for soluble dopamine

receptors by the precipitation method.  Eur. J. Pharmacol. 74: 53-59 (1981).


237. WATANABE, S. and SEEMAN, P.: Dopamine receptors in lesion-produced hyperactive rats.

8th Int. Congr. Pharmacol. Abstr. (Tokyo, 1981), p. 829 (Abstr. 0-37).


238.[161]. SEEMAN, P., and LIST, S.:  Dopamine receptors and dopaminergic supersensitivity.  In:

Neurotransmitter Receptors, Adv. Pharmacol. Therap. II, 2, edited by H. Yoshida, Y.

Hagihara and S. Ebashi, Pergamon Press, New York, pp. 41-49, 1982.


239.[163]. SEEMAN, P. and LEE, T.: Dopamine receptors in the schizophrenic brain. In: Psychobiology

of Schizophrenia (C.u.O. Vogt and M. Hayashi symposium, Gifu, Japan, 1981), edited by M.

Namba and H. Kaiya, Pergamon Press, pp. 241-247, 1982.


240.[164]. SEEMAN, P. and LIST, S.:  Multiple receptors for dopamine (D2, D3, D4).  In:  Advances in

Dopamine Research.  Advances in the Biosciences 37, M. Kohsaka, edited by G.N. Woodruff,

T. Shohmori and Y. Tsukada, Pergamon Press, New York, pp. 61-70, 1982.


241. DAVIS, A., MADRAS, B.K., LILLY, L. and SEEMAN, P.: Solubilized 3H-dopamine

receptors (D3) of dog striatum.  Fed. Proc. 40: 291 (1981).


243.[165]. SEEMAN, P.:  Dopamine receptors in post-mortem schizophrenic brains.  Lancet i: 1103

(1981).    


244.[166]. MADRAS, B.K., DAVIS, A. and SEEMAN, P.: Comparison of soluble dopamine D2-

receptors from three species. Eur. J. Pharmacol. 78: 431-438 (1982).


245. HARTLEY, E.J. and SEEMAN, P.: Alpha-adrenoceptor development and hyperlocomotion

in young rats. Soc. Neurosci. Abstr. 7: 125 (1981).


246. HELMESTE, D.M. and SEEMAN, P.: Dopamine receptors, amphetamine response, and

hyperkinetic syndrome.  Soc. Neurosci. Abstr. 7: 12 (1981).


247. LIST, S. and SEEMAN, P.:  D3 and D4 dopaminergic binding sites detected by 3H-ADTN. 

Soc. Neurosci. Abstr. 7: 10 (1981).


248. CHAN, B., SEEMAN, P., DUMBRILLE-ROSS, A. and MADRAS, B.K.: Solubilization and

partial purification of 3H-mianserin binding sites.  Soc. Neurosci. Abstr. 7: 7 (1981).


249. MADRAS, B.K., DAVIS, A., LILLY, L., FRASER, C., VENTER, C. and SEEMAN, P.: 

Partially purified dopamine/neuroleptic receptors (D2-type).  Soc. Neurosci. Abstr. 7: 10

(1981).


250. DAVIS, A., FRASER, C.M., LILLY, L., MADRAS, B.K., VENTER, J.C. and SEEMAN, P.:

Monoclonal antibodies to partially purified D2 dopamine receptors.  Soc. Neurosci. Abstr. 7:

10 (1981).


251. LEE, T and SEEMAN, P.:  Pre- and post-synaptic dopamine receptors in schizophrenia.

Progr. Neuropsychopharmacol. 5(3):  283 (1981).


252.[167]. MADRAS, B.K., DAVIS, A., CHAN, B. and SEEMAN, P.: Solubilized

dopamine/neuroleptic receptors (D2-type).  Progr. Neuropsychopharmacol. 5(3): 543-548

(1981).


253. DAVIS, A., LILLY, L., FRASER, C., VENTER, J.C., MADRAS, B.K. and SEEMAN, P.:

Characterization of partially purified neuroleptic/dopamine (D2-type) receptors and

subsequent antibody production. Progr. Neuropsychopharmacol. 5(3): 283 (1981).


254. LEE, T., LEE, S.L. and SEEMAN, P.: Dopamine receptor regulation in the rat. Progr.

Neuropsychopharma-col. 5(3): 283 (1981).


255. HELMESTE, D.M. and SEEMAN, P.: Genetic differences in CNS dopamine receptors and

possible relations to amphetamine-induced locomotion in mice. Progr.

Neuropsychopharmacol. 5(3): 283 (1981).


256. LILLY, L., DAVIS, A., MADRAS, B.K., FRASER, C.M., VENTER, J.C. and SEEMAN, P.:

Brain D2 dopamine receptors: partial purification.  Soc. Neurosci. Abstr. 7: 10 (1981).


257.[168]. HARTLEY, E.J. and SEEMAN, P.: Development of receptors for dopamine and

noradrenaline in rat brain. Europ. J. Pharmacol. 91: 391-398 (1983).


258. DAVIS, A., FRASER, C.M., LILLY, L., MADRAS, B.K., SEEMAN, P. and VENTER, J.C.:

Partial purification of brain D2 dopamine receptors and the development of monoclonal

antibodies. Neurosci. Lett. 7:  S191 (1981).


259. SEEMAN, P. and LEE, T.:  Brain dopamine receptors in schizophrenia. 134th Amer.

Psychiat. Assoc. Abstr. p. 38 (1981), Abstr. 16B.


260.[169]. CHAN, B., SEEMAN, P., DAVIS, A. and MADRAS, B.K.: Ascorbate injury and EDTA (or

manganese) protection of dopamine receptors. Eur. J. Pharmacol. 81: 111-116 (1982).


261.[170]. HELMESTE, D.M. and SEEMAN, P.: Amphetamine-induced hypolocomotion in mice with

more brain D2 dopamine receptors. Psychiat. Res. 7: 351-360 (1982).


262.[171]. HELMESTE, D.M. and SEEMAN, P.: 3H-Haloperidol binds to more than one site in rat brain

striatum. Biochem. Pharmacol. 32: 741-744 (1983).


263.[172]. TITELER, M. and SEEMAN, P.: Effects of anti-hypertensive clonidine congeners on alpha-

adrenergic receptors. Canad. J. Physiol. Pharmacol. 60: 342-344 (1982)


264.[173]. LIST, S.J., WREGGETT, K.A. and SEEMAN, P.: Striatal binding of 3H-ADTN to two

dopaminergic sites distinguished by their low and high affinity for neuroleptics. J. Neurosci.

2: 895-906 (1982).


265.[174]. LILLY, L., DAVIS, A., FRASER, C.M., SEEMAN, P. and VENTER, J.C.:  Characterization

of brain D2 dopamine receptors.  Neurochem. Internat. 7: 363-368 (1985).


266.[175]. LIST, S. and SEEMAN, P.:  3H-Dopamine labelling of D3 dopaminergic sites in human, rat

and calf brain. J. Neurochem. 39: 1363-1373 (1982).


267.[176]. SEEMAN, P.: Nomenclature of central and peripheral dopaminergic sites and receptors.

Biochem. Pharmacol. 31: 2563-2568 (1982).


268.[177]. SEEMAN, P. and SEEMAN, M.V.: Schizophrenia and dopamine receptors. Psychiat. Newsl.

Univ. Toronto 1: p.l (1981).


269.[178]. SEEMAN, P., ULPIAN, C., WREGGETT, K.A. and WELLS, J.: Dopamine receptor

parameters detected by 3H-spiperone depend on tissue concentration: analysis and examples. 

J. Neurochem. 43: 221-235 (1984).


270.[179]. SEEMAN, P.: Dopamine receptor measurement with 3H-ligands.  In:  Methods in Biogenic

Amine Research, edited by S. Parvez, T. Nagatsu and H. Parvez, Elsevier Science, B.V.,

Amsterdam, 1983, pp. 591-622.


271.[180]. SEEMAN, P.: Schizophrenia and dopamine receptors. In: A method of psychiatry, edited by

S.E. Greben, V.M. Rakoff, G. Voineskos, Lea & Febiger, Philadelphia, 1985, pp. 70-77.


272.[181]. WREGGETT, K. and SEEMAN, P.: Classification and agonist requirements of dopamine

receptors. In:  Dopamine Receptor Agonists, edited by A. Carlsson and J.L.G. Nilsson,

Swedish Pharmaceutical Press,  Stockholm, 1983, pp. 30-40; Acta Pharmaceut. Suec. Suppl.

1:  30-40 (1983).


273.[182]. SEEMAN, P.: Dopamine receptors in brain. In: Brain receptor methodologies, Part A, edited

by P.J. Marangos, I.C. Campbell, and R.M. Cohen, Academic Press, 1984, pp. 285-307.


274. SEEMAN, P., ULPIAN, C. and WELLS, J.: Dopamine receptor parameters (detected by 3H-

spiperone) depend on tissue concentration. Soc. Neurosci. Abstr. 8: 718 (1982).


275. WREGGETT, K.A., GEORGE, S.R. and SEEMAN, P.: Modulation of the D2 dopamine

receptor in calf caudate by guanine nucleotide. Soc. Neurosci. Abstr. 8: 719 (1982).      


276. GEORGE, S.R., WREGGETT, K.A. and SEEMAN, P.: Dopaminergic binding sites in the

anterior pituitary discriminated by agonists and guanine nucleotides. Soc. Neurosci. Abstr. 8:

720 (1982).


277. LILLY, L., MAGNAN, J., DAVIS, A. and SEEMAN, P.: Irreversible 3H-ligands for

dopamine receptor purification. Soc. Neurosci. Abstr. 8: 719 (1982).


278.[183]. OTTON, S.V., KALOW, W. and SEEMAN, P.: High affinity of quinidine for a

stereoselective microsomal binding site as determined by a radioreceptor assay. Experientia

40: 973-974 (1984).


279.[184]. GEORGE, S., BINKLEY, K. and SEEMAN, P.: Dopamine receptor sites and states in human

brain. J. Neural Transm. Suppl. 18: 149-156 (1983).


280.[185]. GEORGE, S., WATANABE, M. and SEEMAN, P.: Commentary: The dopamine receptor of

the anterior pituitary gland. In: Dopamine Receptors, edited by C. Kaiser and J. Kebabian,

Amer. Chem. Soc. Symp. 224, Amer. Chem. Soc., Washington, pp. 93-99, 1983.


281. HATTORI, T., WEINREICH, P. and SEEMAN, P.: Implications of trans-synaptic

degeneration for receptor binding studies in the rat striatum. Soc. Neurosci. Abstr. 8: 646

(1982).


282.[186]. WREGGETT, K.A. and SEEMAN, P.: Agonist high- and low-affinity states of the D2

dopamine receptor in calf brain:  partial conversion by guanine nucleotide. Mol. Pharmacol.

25:  10-17 (1984).


283. SEEMAN, P.: This week's Citation Classic. Curr. Cont. Life Sci. 26(4):  22 (1983).


284.[187]. RAJPUT, A.H., ROZDILSKY, B., HORNYKIEWICZ, O., SHANNAK, K., LEE, T. and

SEEMAN, P.: Reversible drug-induced Parkinsonism. Clinicopathologic study of two cases. 

Arch. Neurol. 39: 644-646 (1982).


285.[188]. LILLY, L., FRASER, C.M., JUNG, C., SEEMAN, P. and VENTER, J.C.: Molecular size of

the canine and human brain D2 dopamine receptor as determined by radiation inactivation.

Mol. Pharmacol. 24: 10-14 (1983).


286. SEEMAN, P., ULPIAN, C. and TOURTELLOTTE, W.W.: Elevation of D2 dopamine

receptors in schizophrenia brain. Int. Congr. Neurochem. Abstr. (Vancouver). J. Neurochem.

41 Suppl.: p. S33 (1983).


287. GEORGE, S., WATANABE, M. and SEEMAN, P.: Regulation of the states of the D2

dopamine receptor in the anterior pituitary.  In:  Current Frontiers in Catecholamine Research.

(5th Int. Catecholamine Symp. Abstr., Goteborg), edited by E. Usdin, A. Carlsson, A.

Dahlstrom and J. Engel, Pergamon, Oxford (1983); Prog.  Neuropsychopharmacol. Biol.

Psychiatr. Suppl. (1983), abstr. 170, p. 145.


288.[189]. GRIGORIADIS, D. and SEEMAN, P.: Complete conversion of brain D2 dopamine receptors

from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine

nucleotide.  J. Neurochem. 44:  1925-1935 (1985).


289.[190]. GEORGE, S.R., WATANABE, M. and SEEMAN, P.: Dopamine D2 receptors in the anterior

pituitary:  A single population without reciprocal agonist/antagonist states.  J. Neurochem. 44:

1168-1177 (1985).


290. GEORGE, S.R., WATANABE, M. and SEEMAN, P.: The dopamine receptor of the anterior

pituitary gland. Int. Congr. Neurochem. Abstr. (Vancouver).  J. Neurochem. 41 Suppl.: p.

S110 (1983).


291.[191]. WATANABE, S. and SEEMAN, P.: Dopamine receptor density in rat striatum over 24

hours: Lack of detectable changes. Biol. Psychiat. 19: 1249-1253 (1984).


292.[192]. SEEMAN, P. and ULPIAN, C: Neuroleptics have identical potencies in human brain limbic

and putamen regions. Europ. J. Pharmacol. 94: 145-148 (1983).


293. SEEMAN, P., ULPIAN, C. and TOURTELLOTTE, W.W.: Elevation of D2 dopamine

receptors in schizophrenia brain. Soc. Neurosci. Abstr. 9: 31 (1983).


294.[193]. GUAN, J.-H., NEUMEYER, J.L., FILER, C.N., AHERN, D.G., LILLY, L., WATANABE,

M., GRIGORIADIS, D. and SEEMAN, P.: Aporphines. 58. N-(2-Chloroethyl)-[8,9-

2

H]norapomorphine, an irreversible ligand for dopamine receptors:  synthesis and application.

J. Med. Chem. 27: 806-809 (1984).


295.[194]. VENTER, J.C., FRASER, C.M., LILLY, L., SEEMAN, P., EDDY, B. and SCHABER, J.:

The structure of neurotransmitter receptors (adrenergic, dopaminergic and muscarinic cholinergic). In: Catecholamine Research (5th Int. Catecholamine Symp., Goteborg), edited

by E. Usdin, A. Carlsson, A. Dahlstrom and J. Engel, Pergamon, Oxford, (1984); Progr.

Neuropsychopharmacol. Biol. Psychiatr. Suppl. (1983), (Abstr. 506: p. 307).


296. GEORGE, S.R., WATANABE, M. and SEEMAN, P.: The brain D2 dopamine receptor

differs from the pituitary D2 receptor, as detected by (-)3-PPP.  Soc. Neurosci. Abstr. 9: 31

(1983).


297. GRIGORIADIS, D. and SEEMAN, P.: Sodium ions convert brain D2 dopamine receptors

from high to low affinity for dopamine agonists. Soc. Neurosci. Abstr. 9: 31 (1983).


298. LILLY, L.B. and SEEMAN, P.: D2 dopamine receptor purification using 3H-NCA:

Identification of a 40,000 dalton binding protein. Soc. Neurosci. Abstr. 9: 30 (1983).


299. WATANABE, M., GEORGE, S.R. and SEEMAN, P.: The proportion of D2 dopamine

receptors in high and low affinity states depends on the agonist, cations, guanine nucleotides,

and temperature. Soc. Neurosci. Abstr. 9: 994 (1983).


300.[195]. SEEMAN, P.: Brain dopamine receptors. Pharmacol. Rev. 32: 229-313 (1980).


301. MICHNICK, S., and SEEMAN, P.: Incorporation of functional dopamine receptors into

planar lipid bilayer membranes. Soc. Neurosci. Abstr. 9: 1144 (1983).


302.[196]. MADRAS, B.K. and SEEMAN, P.: Drug potencies on partially purified brain D2 dopamine

receptors. J. Neurochem. 44: 856-861 (1985).


304.[197]. GRIGORIADIS, D. and SEEMAN, P.: The dopamine/neuroleptic receptor. Canad. J. Neurol.

Sci. 11: 108-113 (1984).


305. GEORGE, S.R., WATANABE, M. and SEEMAN, P.: Guanine nucleotides and sodium ions

modulate the sensitivity of anterior pituitary dopamine receptors to dopamine agonists and

antagonists. 7th Int. Congr. Endocrinol.  Abstr. (July, 1984), p. 573, Abstr. 626, Elsevier

Science B.V. (1984).


306.[198].  TANG, S.W., GLAISTER, J., DAVIDSON, L., TOTH, R., JEFFRIES, J.J. and SEEMAN,

P.: Total and free plasma neuroleptic levels in schizophrenic patients. Psychiatry Res. 13:

285-293 (1984).


307.[199]. SEEMAN, P., ULPIAN, C., BERGERON, C., RIEDERER, P., JELLINGER, K., GABRIEL,

E., REYNOLDS, G.P. and TOURTELLOTTE, W.W.: Bimodal distribution of dopamine

receptor densities in brains of schizophrenics. Science 225: 728-731 (1984).


308.[200]. SEEMAN, P.: Brain dopamine receptors in schizophrenia.  In: New Perspectives in

Schizophrenia. M.N. Menuck and M.V. Seeman (Eds.), Macmillan Publ. Co., New York,

1985, pp. 71-79.


309.[201]. SEEMAN, P.: Dopamine receptors. In: Discussions in Neuroscience 2: 56-58 (1985), Brain

metabolism and imaging, edited by W. Feindel, R.S.J. Frackowiak, D. Gadian, P.L.

Magistretti and M.R. Zalutsky, Fondation pour 1'Etude du Systeme Nerveux Central et

Peripherique, Geneva.


310. SEEMAN, P.: Brain catecholamine receptors. 14th Northeastern Regional Mtng., Amer.

Chem. Soc. Abstr. (Fairfield, June 1984), p. 34, Abstr. 67 (1984).


311.[202]. SEEMAN, P.: Brain dopamine receptors in schizophrenia. In: Neuroreceptor Mechanisms in

Human Diseases, B.M. edited by Conti-Tronconi, M. Fanciullacci, F. Sicuteri and L.

Terenius, Menarini Foundation, Florence, March 1984.


312.[203]. GEORGE, S.R., WATANABE, M., DI PAOLO, T., FALARDEAU, P., LABRIE, F., &

SEEMAN, P.: The functional state of the dopamine receptor in the anterior pituitary is in the

high-affinity form. Endocrinology 117: 690-697 (1985).


313. SEEMAN, P., GEORGE, S.R., WATANABE, M. and GRIGORIADIS, D.: Pituitary and

presynaptic D2 dopamine receptors function in high-affinity state for dopamine. Postsynaptic

ones are in a low-affinity state. 9th Int. Congr. Pharmacol. Abstr. (London, July 1984), Abstr.

484.


314.[204]. HELMESTE, D.M. and SEEMAN, P.: Genetic differences in brain dopamine receptors and

amphetamine response: Possible model for hyperkinetic children. In: Developmental

Pharmacology, edited by S.M. MacLeod, A.B. Okey and S.P. Spielberg, Alan R. Liss, Inc.,

New York, pp. 401-403 (1983).


315.[205]. SEEMAN, P., GRIGORIADIS, D., GEORGE, S.R., WATANABE, M. and ULPIAN, C:

Functional states of dopamine receptors. In: Dopaminergic Systems and Their Regulation,

edited by G.N. Woodruff, J.A. Poat and P.J. Roberts, Macmillan Press, London (1986), pp.

97-109.


316.[206]. SEEMAN, P.: Brain dopamine receptors in schizophrenia and tardive dyskinesia. In:

Dyskinesia, Research and Treatment, edited by D. Casey, T. Chase, A.V. Christensen and J.

Gerlach, Psychopharmacology Supple-mentum series, Vol. 2, Springer-Verlag Berlin (1985),

pp. 2-8.


317. SEEMAN, P., GEORGE, S.R., and WATANABE, M.: Presynaptic dopamine receptors

operate in the high-affinity state for dopamine. Post-synaptic ones work in low-affinity state.

Soc. Neurosci. Abstr. 10: 278 (1984).


318.[207]. NIZNIK, H.B., GUAN, J.H., NEUMEYER, J.L., and SEEMAN, P.: A dopamine D2 receptor

photolabel:  azidoclebopride. Europ. J. Pharmacol. 104: 389-390 (1984).


319.[208]. DUMBRILLE-ROSS, A., and SEEMAN, P.: Dopamine receptor elevation by

cholecystokinin. Peptides 5:  1207-1212 (1985).


320.[209]. SEEMAN, P.: Dopamine/neuroleptic receptors in schizophrenia. In: Handbook of Studies in

Schizophrenia, Part 2, edited by G.D. Burrows, T.R. Norman and G. Rubinstein, Elsevier

Science B.V. (Biomedica Div.), Am-sterdam, 1986, pp. 251-259.


321. DUMBRILLE-ROSS, A., & SEEMAN, P.: Dopamine receptor elevation by cholecystokinin.

Soc. Neurosci. Abstr. 10: 536 (1984).


322. GEORGE, S.R., WATANABE, M., and SEEMAN, P.: D2 dopamine receptor interactions

with agonists and antagonists are modulated by sodium ions. Soc. Neurosci. Abstr. 10: 278

(1984). 


323. FALARDEAU, P., DI PAOLO, T., LABRIE, F., GEORGE S., WATANABE, M., and

SEEMAN, P.: The functional state of the dopamine receptor in the anterior pituitary is the

high-affinity form. Soc. Neurosci. Abstr. 10: 240 (1984).


324. GRIGORIADIS, D., GEORGE, S.R., WATANABE, M., and SEEMAN, P.: Dopamine D2

receptor density increases markedly, using constant infusion of haloperidol by osmotic pump.

Soc. Neurosci. Abstr. 10: 241 (1984).


325. NIZNIK, H.B., GRIGORIADIS, D., PRI-BAR, BUCHMAN, O., and SEEMAN, P.:

Dopamine D2 receptors labeled by a new high-affinity ligand:  3H-YM-09151.  Soc. Neurosci.

Abstr. 10: 277 (1984).


326.[210]. WATANABE, M., GEORGE, S.R., and SEEMAN, P.: Dependence of dopamine receptor

conversion from agonist high- to low-affinity state on temperature and sodium ions. Biochem.

Pharmacol. 34:2459-2463 (1985).


327. WATANABE, M., GEORGE, S.R., and SEEMAN, P.: Dopamine receptor regulation in

brain and pituitary. 14th Mtng. Jap. Soc. Psychopharmacol. Abstr. (1984).


328.[211]. NIZNIK, H.B., GUAN, J.H., NEUMEYER, J.L., and SEEMAN, P.: A photoaffinity ligand

for dopamine D2 receptors: azidoclebopride.  Mol. Pharmacol. 27: 193-199 (1985).


329.[212]. SEEMAN, P., ULPIAN, C., GRIGORIADIS, D., PRI-BAR, I., and BUCHMAN, O.:

Conversion of dopamine D1 receptors from high to low affinity for dopamine. Biochem.

Pharmacol. 34: 151-154 (1985).


330.[213]. NIZNIK, H.B., GRIGORIADIS, D.E., PRI-BAR, I., BUCHMAN, O., and SEEMAN, P.:

Dopamine D2 receptors are selectively labeled by a benzamide neuroleptic:  3H-YM-09151-2.

Naunyn-Schmiedeberg's Arch. Pharmacol. 329: 333-343 (1985).


331.[214]. NIZNIK, H.B., DUMBRILLE-ROSS, A., GUAN, J.H., NEUMEYER, J.L., and SEEMAN,

P.: Dopamine D2 receptors photolabeled by iodo-azido-clebopride. Neurosci. Lett. 55: 267-

272 (1985).


332.[215]. GEORGE, S.R., WATANABE, M., and SEEMAN, P.: Dopamine D2 receptors in brain and

anterior pituitary recognize agonist and antagonist actions of (-)-3-PPP.  J. Neural Transm. 64:

13-33 (1985).


333. RAMSBY, S.R., WATANABE, M., and SEEMAN, P.: 2-Amino- and 2-halo-aporphines as

ligands for the dopamine receptor. Int. Med. Chem. Mtng. Abstr., Uppsala (1984).


334.[216]. SEEMAN, M.V., and SEEMAN, P.: Molecular Psychiatry, Receptor density and Receptor

sensitivity states.  Integrative Psychiatry 4: 41-43 (1986).


335.[217]. NEUMEYER, J.L., GUAN, J.-H., NIZNIK, H.B. DUMBRILLE-ROSS, A., SEEMAN, P.,

PADMAN-ABHAN, S., and ELMALEH, D.: Novel photoaffinity label for the dopamine D2

receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-

piperidinyl]benzamide (Iodoazidoclebopride, IAC) and the corresponding 125I-labelled

analogue. J. Med. Chem. 28: 405-407 (1985).


336.[218]. SEEMAN, P. and GRIGORIADIS, D.: Dopamine receptors in brain and periphery.

Neurochem. Int. 10: 1-25 (1987).


337.[219]. DUMBRILLE-ROSS, A., & SEEMAN, P.: Dopamine agonist high-affinity state in

solubilized D2 receptors in striatum, but not in anterior pituitary. Biochem. Pharmacol. 36:

2095-2099 (1987).  


338. GUAN, J.-H., NEUMEYER, J.L., NIZNIK, H.B., DUMBRILLE-ROSS, A., SEEMAN, P.,

ELMALEH, D. and PADMANABHAN, S.: Novel photoaffinity label for the dopamine D2

receptor:  Iodoazidoclebopride and the corresponding 125I-labeled analog. 189th Amer. Chem.

Soc. Med. Chem. Div. Abstr. (1985), Abstr. 92.


339.[220]. GUTTMAN, M., and SEEMAN, P.: Dopamine D2 receptor density in Parkinsonian brain is

constant for duration of disease, age and duration of L-DOPA therapy.  Adv. Neurol. 45: 51-

57 (1986).


340. ELMALEH, D.R., PADMANABHAN, S., GUAN, J.-H., NEUMEYER, J.L., NIZNIK, H.B.,

and SEEMAN, P.: The in-vivo distribution of a novel photoaffinity label for the dopamine

D2 receptor. 12th Int. Symp. Cerebral blood flow and metabolism Abstr. (Lund) 1985.


342.[221]. WATANABE, M., GEORGE, S.R., and SEEMAN, P.: Regulation of anterior pituitary D2

dopamine receptors by magnesium and sodium ions. J. Neurochem. 45:  1842-1849 (1985).


343.[222]. SEEMAN, P., WATANABE, M., GRIGORIADIS, D., TEDESCO, J.L., GEORGE, S.R.,

SVENSSON, U., NILSSON, J.L.G., and NEUMEYER J.L.: Dopamine D2 receptor binding

sites for agonists: A tetrahedral model.  Mol. Pharmacol. 28: 391-399 (1985).


344. GEORGE, S.R., and SEEMAN, P.: Regulation of the high and low agonist-affinity states of

dopamine receptors.  Canad. Fed. Biol. Soc. Abstr. 28:  p. 29 (Abstr. S-58) (1985).


345.[223]. DUMBRILLE-ROSS, A. NIZNIK, H., and SEEMAN, P.: Separation of dopamine D1 and D2

receptors. Europ. J. Pharmacol. 110: 151-152 (1985).


346.[224]. GUTTMAN, M., SEEMAN, P., BERGERON, C., RIEDERER, P., JELLINGER, K., and

TOURTEL-LOTTE, W.W.: Dopamine D2 receptor density remains constant in treated

Parkinson's disease. Annals Neurol. 19:  487-492 (1986).


347.[225]. SEEMAN, P., and GRIGORIADIS, D.: Dopamine D2 receptor dissociation constant for

spiperone:  Identical values using 3H-labeled agonist or 3H-labeled antagonist. Biochem.

Pharmacol. 34:  4065-4066 (1985).


348.[226]. HORN, A.S., TEPPER, P., VAN DER WEIDE, J., WATANABE, M., GRIGORIADIS, D.,

and SEEMAN, P.: Synthesis and radioreceptor binding activity of N-0437, a new, extremely

potent and selective D2 dopamine receptor agonist. Pharmaceutisch Weekblad Sci. Ed. 7: 208-

211 (1985).


349.[227]. NIZNIK, H.B., OTSUKA, N.Y., DUMBRILLE-ROSS, A., GRIGORIADIS, D., TIRPAK, A.,

and SEEMAN, P.: Dopamine D1 receptors characterized with [3H]-SCH-23390.

Solubilization of a guanine nucleotide-sensitive form of the receptor. J. Biol. Chem. 261: 

8397-8406 (1986).


350.[228]. GUTTMAN, M., and SEEMAN, P.: L-DOPA reverses the elevated D2 dopamine receptor

density in Parkinson's diseased striatum. J. Neural Transm. 64: 93-103 (1985).


351. RAMSBY, S., NEUMEYER, J., and SEEMAN, P.: 2-Fluoroapomorphine, a potent ligand for

the dopamine receptor. 189th Amer. Chem. Soc. Div. Med. Chem. Abstr. (1985), Abstr. 91.


352.[229]. GRIGORIADIS, D., and SEEMAN, P.: 3H-Domperidone labels only a single population of

receptors which convert from high to low affinity for dopamine in rat brain. Naunyn-

Schmiedeberg's Arch. Pharmacol. 332: 21-25 (1986).


353. BZOWEJ, N.H., and SEEMAN, P.: Age and dopamine D1 and D2  receptors in human brain.

Soc. Neurosci. Abstr. 11: 889 (1985).


354. DUMBRILLE-ROSS, A., NIZNIK, H.B., and SEEMAN, P.: Dopamine D1 amd D2 receptor

interactions. Soc. Neurosci. Abstr. 11: 716 (1985).


355.[230]. SEEMAN, P.: Dopamine receptors in human brain diseases. In: Structure and function of

dopamine receptors, edited by I. Creese and C.M. Fraser, vol 9 of Receptor Biochemistry and

Methodology, Alan R. Liss, New York, 1987, pp. 233-245.


356.[231]. KOHNO, A., SEEMAN, P., and CINADER, B.: Age-related changes of beta-adrenoceptors

in aging inbred mice.  J. Gerontol. 41: 439-444 (1986).


357.[232]. SEEMAN, P.: Schizophrenia and dopamine receptors. In: New Perspectives in Treatment of

Schizophrenia, edited by D.A.W. Johnson, Symp. of World Psychiatr. Assoc. (1985), H.

Lundbeck A/S, Copenhagen, 1986, pp. 8-14.


358.[233]. ELMALEH, D.R., PADMANABHAN, S., NIZNIK, H.B., SEEMAN, P., GUAN, J.-H., and

NEUMEYER, J.L.: In vivo evaluation of 125I-labeled iodoclebopride and iodoazidoclebopride

binding to the dopamine D2 receptor.  In: Alzheimer's and Parkinson's Disease, edited by A.

Fisher, I. Hanin and C. Lachman. Plenum publishing Corp., New York, 1986, pp. 645-653.


359.[234]. SEEMAN, P.: The absolute density of neurotransmitter receptors in brain: example for

dopamine receptors. J. Pharmacol. Methods 17:  347-360 (1987).


360.[235]. NIZNIK, H.B., GRIGORIADIS, D.E., OTSUKA, N.Y., DUMBRILLE-ROSS, A., and

SEEMAN, P.: The dopamine D1 receptor: Partial purification of a digitonin-solubilized

receptor-guanine nucleotide binding complex. Biochem. Pharmacol. 35:  2974-2977 (1986).


361.[236]. SEEMAN, P., GRIGORIADIS, D., and NIZNIK, H.B.: Selectivity of agonists and

antagonists at D2 dopamine receptors compared to D1 and S2 receptors. Drug Dev. Res. 9:  63-

69 (1986).


362. SEEMAN, P., and GEORGE, S.R.: Dopamine receptor regulation. Amer. Soc. Neurochem.

Abstr. (17th Annu. Meet.): 329, Abstr. 473 (1986).


363.[237]. SEEMAN, P.: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse

1: 133-152 (1987).


364.[238]. KOHNO, A., SEEMAN, P., and CINADER, B.: Age-related changes in beta-adrenoceptors

of lymphocytes.  Immunology Lett. 13: 79-82 (1986).


365.[239]. SEEMAN, P., and NIZNIK, H.B.: Dopamine D2 receptors photolabelled by [3H]-azido-

methylspiperone.  Europ. J. Pharmacol. 127: 297-299 (1986).


366.[240]. NIZNIK, H.B., GRIGORIADIS, D.E., and SEEMAN, P.: Photoaffinity labelling of

dopamine D2 receptors by [3H]azidomethylspiperone. FEBS Lett. 209: 71-76 (1986).


367. BZOWEJ, N.H., and SEEMAN, P.: Dopamine D1 and D2 receptors in Huntington's chorea.

Soc. Neurosci. Abstr. 12: 1248 (1986).


368.[241]. SEEMAN, P., and GUTTMAN, M.: Dopamine receptor elevation in denervated tissues. Ann.

Neurol. 21:  412-413 (1987).


369.[242]. KOHNO, A., CINADER, B., and SEEMAN, P.:Age-related changes of beta-adrenoceptors in

spleen lymphocytes and cerebral cortex of NZB/BIN mice. Immunol. Lett. 14: 75-78

(1986/1987).


370.[243]. SEEMAN, P., BZOWEJ, N.H., GUAN, H.-C., BERGERON, C., BECKER, L.E.,

REYNOLDS, G.P., BIRD, E.D., RIEDERER, P., JELLINGER, K., WATANABE, S., and

TOURTELLOTTE, W.W.: Human brain dopamine receptors in children and aging adults.

Synapse 1: 399-404 (1987).


371. SEEMAN, P., and SEEMAN, M.V.: Review of "Antipsychotics", edited by G.D. Burrows et

al., Amer J. Psychiat.  144: 519-520 (1987).


372. SEEMAN, P.: Review of "Neuromethods. Series 1: Neurochemistry 4:  Receptor binding",

edited by A.A. Boulton, G.B. Baker and P.D. Hrdina.  J. Med. Chem. 30: 449-450 (1987).


373.[244]. EL-AWAR, M., FREEDMAN, M., SEEMAN, P., GOLDENBERG, L., LITTLE, J., and

SOLOMON, P:  Response of tardive and L-DOPA-induced dyskinesias to antidepressants.

Can. J. Neurolog. Sci. 14: 629-631 (1987).


374.[245]. BZOWEJ, N.H., NIZNIK, H.B., and SEEMAN, P.: Dopamine D1 receptors with enhanced

agonist affinity and reduced antagonist affinity revealed by chemical modification. Biochem.

Biophys. Res. Communic. 152:  933-939 (1988).


375.[246]. GRIGORIADIS, D.E., NIZNIK, H.B., JARVIE, K.R., and SEEMAN, P.: Glycoprotein

nature of D2 dopamine receptors. FEBS Lett. 227: 220-224 (1988).


376.[247]. REYNOLDS, G.P., CZUDEK, D., BZOWEJ, N., and SEEMAN, P.: Dopamine receptor

asymmetry in schizophrenia. Lancet i: 979 (1987).


377.[248]. SEEMAN, P., BZOWEJ, N.H., GUAN, H.-C., BERGERON, C., REYNOLDS, G.P., BIRD,

E.D., RIEDERER, P., JELLINGER, K., and TOURTELLOTTE, W.W.: Human brain D1 and

D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases.

Neuropsychopharmacology 1: 5-15 (1987).


378.[249]. NIZNIK, H.B., FOGEL, E.L., CHEN, C.J., CONGO, D., BROWN, E.M., and SEEMAN, P.:

Dopamine D1 receptors of the calf parathyroid gland: Identification and characterization. Mol.

Pharmacol. 34: 29-36 (1988).


379.[250]. SEEMAN, P., and GUAN, H.-C.: Dopamine D1 and D2 receptors are sensitive to the cationic

form of apomorphine. Mol. Pharmacol. 32: 760-763 (1987).


380.[251]. SEEMAN, P. and ULPIAN, C.: Dopamine D1 and D2 receptor selectivities of agonists and

antagonists.  In: Central D1 Dopamine Receptors, edited by M. Goldstein, K. Fuxe, and I.

Tabachnick. Plenum Publ. Corp., New York, pp. 55-63 (1988).


381.[252]. JARVIE, K.R., NIZNIK, H.B., and SEEMAN, P.: Brain dopamine D2 receptors: ionic effects

on [3H]neuroleptic binding. Eur. J. Pharmacol. 144: 163-171 (1987).


382. BZOWEJ, N.H., NIZNIK, H.B., GRIGORIADIS, D.E., and SEEMAN, P.: Dopamine D1

receptors: effects of thiol modifying reagents. Soc. Neurosci. Abstr. 13: 1198 (1987). 


383. GRIGORIADIS, D.E., NIZNIK, H.B. and SEEMAN, P.: Dopamine D2 receptor ligand

binding subunit detected by photoaffinity labeling. Soc. Neurosci. Abstr. 13: 190 (1987).


384. JARVIE, K., NIZNIK, H.B., and SEEMAN, P.: Dopamine D2 receptors: Effects of ions on

[3H]neuroleptic binding. Soc. Neurosci. Abstr. 13: 1197 (1987).


385. SEEMAN, P.: Review of "The Biochemical Basis of Neuropharmacology", by J.R. Cooper,

F.E. Bloom and R.H. Roth.  Amer. J. Psychiat. 144: 1357 (1987).


386. SEEMAN, P.: Brain dopamine receptors in schizophrenia: PET problems. Arch. Gen.

Psychiat. 45: 598-599 (1988). 


387.[253]. SEEMAN, M.V., and SEEMAN, P.: Psychosis and positron tomography. Canad. J. Psychiat.

33: 299-306 (1988). 


388.[254]. SEEMAN, P.: Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell

membranes. J. Clin. Psychopharmacol. 8: 3S-9S (1988).


389.[255]. SEEMAN, P., and NIZNIK, H.B.: Dopamine D1 receptor pharmacology. ISI Atlas of Sci.

Pharmacol. 2: 161-170 (1988).


390. GUTTMAN, M., KEBABIAN, J.W., FIBIGER, H.C., JAKUBOVIC, A., SCHOENLEBER,

R., ADAM, M.J., RUTH, T.J., GROWCHOWSKI, E., SEEMAN, P., GUAN, H.-C., and

CALNE, D.B.: Unilateral MPTP lesioned monkeys, 2:  Reduced striatal D-1 binding with

SCH 23390 PET Scans. 9th Int. Symp. Parkinson's Dis., Abstr. (1988).


391.[256]. JARVIE, K.R., NIZNIK, H.B., and SEEMAN, P.: Dopamine D2 receptor binding subunits of

Mr 140 000 and 94 000 in brain:  Deglycosylation yields a common unit of Mr 44 000. Mol.

Pharmacol. 34: 91-97 (1988).


392.[257]. NEUMEYER, J.L., BAINDUR, N., YUAN, J., BOOTH, G., SEEMAN, P., and NIZNIK,

H.B.: Development of high affinity and stereoselective photoaffinity label for the D-1

dopamine receptor: Synthesis and resolution of IMAB and [125I]I-MAB.  J. Med. Chem. 33:

521-526 (1990).


393. SALLEE, F.R., STILLER, R.L., NIZNIK, H.B., BZOWEJ, N.H., SEEMAN, P., and PEREL,

J.M.: Solubilization of the dopamine transporter. Soc. Neurosci. Abstr. 14: 930 (1988).


394. BZOWEJ, N.H., NIZNIK, H.B., and SEEMAN, P.: Photoaffinity labelling of human brain D2

dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases.

Soc. Neurosci. Abstr. 14: 410 (1988).


395. JARVIE, K.R., NIZNIK, H.B., and SEEMAN, P.: Dopamine D2 receptor binding subunits:

Differences in glycosylation account for the existence of high molecular weight forms.  Soc.

Neurosci. Abstr. 14: 454 (1988).


396.[258]. JARVIE, K.R., NIZNIK, H.B., BZOWEJ, N.H., and SEEMAN, P.: Dopamine D2 receptors

retain agonist high-affinity form and guanine nucleotide sensitivity after removal of sialic

acid.  J. Biochem. 104: 791-794 (1988).


397.[259].  SEEMAN, P.: Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and

receptor linkage.  Acta Psychiatr. Scand. 82 (Suppl. 358): 14-20 (1990]. 


398.[260]. NIZNIK, H.B., JARVIE, K.R., BZOWEJ, N.H., SEEMAN, P., GARLICK, R.K., MILLER,

JR., J.J., BAINDUR, N., and NEUMEYER, J.L.: Photoaffinity labeling of dopamine D1

receptors. Biochemistry 27: 7594-7599 (1988).


399.[261]. RAMSBY, S., NEUMEYER, J.L., GRIGORIADIS, D. and SEEMAN, P.: 2-Haloaporphines

as potent dopamine agonists. J. Med. Chem. 32: 1198-1201 (1989).


400.[262]. BAINDUR, N., NEUMEYER, J.L., NIZNIK, H.B., BZOWEJ, N.H., JARVIE, K.R., and

SEEMAN, P.: A photoaffinity label for the D-1 dopamine receptor: (RS)7-[125I]iodo-8-

hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine ([125I]IMAB),

selectively identifies the ligand binding subunits of the receptor.  J. Med. Chem. 31: 2069-

2071 (1988).


401.[263]. NEUMEYER, J.L., NIZNIK, H.B., BZOWEJ, N.H., JARVIE, K.R., SEEMAN, P., and

BAINDUR, N.:  Recent studies in the development of photoaffinity probes for dopamine receptors. In: Trends in Medicinal Chemistry '88, edited by H. van der Goot, G. Domany, L.

Pallos and H. Timmerman. Elsevier Science Publishers B.V., Amsterdam, pp. 543-554

(1989).


402.[264]. SEEMAN, P., GUAN, H.-C., and NIZNIK, H.B.: Endogenous dopamine lowers the

dopamine D2 receptor density as measured by [3H]raclopride:  Implications for positron

emission tomography of the human brain.  Synapse 3: 96-97 (1989).


403. BAINDUR, N., NIZNIK, H.B., SEEMAN, P., and NEUMEYER, J.L.: Iodo-azido-SCH

23390, A novel photoaffinity probe for the D-1 dopamine receptor. 196th Amer. Chem. Soc.

Div. Med. Chem. Meeting, Abstr. 73 (1988).


405.[265]. SEEMAN, P., NIZNIK, H.B., GUAN, H.-C., BOOTH, G. and ULPIAN, C.: Link between

D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.

Proc. Nat. Acad. Sci., U.S.A. 86: 10156-10160 (1989).


406.[266]. WAGNER, JR., H.N., WEINBERGER, D.R., KLEINMAN, J.E., CASANOVA, M.F.,

GIBBS, JR., C.J., GUR, R.E., HORNYKIEWICZ, O., KUHAR, M. J., PETTEGREW, J.W.,

and SEEMAN, P.:  Neuroimaging and neuropathology. Schizophrenia Bull. 14: 383-397

(1988).


407.[267]. PEARCE, R.K.B., SEEMAN, P., JELLINGER, K., and TOURTELLOTTE, W.W.:

Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.

Europ. Neurol.  30 (Suppl. 1): 9-14 (1989).


408.[268]. SEEMAN, P.: Schizophrenia and neurotransmission: Background and current status.

Psychiatry (Toronto) 3: 38-42 (1989).


409. O'DOWD, B.F., NGUYEN, T., TIRPAK, A., JARVIE, K.R., ISRAEL, Y., SEEMAN, P., &

NIZNIK, H.B.: Isolation of an additional G protein-linked receptor from rat brain. FASEB J.

4: A603, Abstr. l953, (1990).


410. SEEMAN, P., NIZNIK, H.B., NGUYEN, T., TIRPAK, A., JARVIE, K.R., ISRAEL, Y., and

O'DOWD, B.F.: Neuroleptic/dopamine receptors: Search for new g-linked receptors. Eur. J.

Pharmacol.l83: 106-107 (1990).


411.[269]. O'DOWD, B.F., NGUYEN, T., TIRPAK, A., JARVIE, K.R., ISRAEL, Y., SEEMAN, P. and

NIZNIK, H.B.: Cloning of two additional catecholamine receptors from rat brain. FEBS

Letters 262: 8-12 (l990).


412.[270]. SEEMAN, P., and NIZNIK, H.B.: Dopamine receptors and transporters in Parkinson's

disease and schizophrenia. FASEB J. 4: 2737-2744 (1990).


413. O'DOWD, B., NGUYEN, T., TIRPAK, A., SUNAHARA, R., SEEMAN, P., NIZNIK, H.B.,

and ISRAEL, Y.: Cloning of two receptors with amino acid homology to the rat D2 dopamine

receptor. Alcoholism, Clin. Exp. Res. 14: 325 (1990).


414.[271]. SEEMAN, P., NIZNIK, H.B., and GUAN, H.-C.: Elevation of D2 dopamine receptors in

schizophrenia is underestimated by radioactive raclopride. Arch. Gen. Psychiat. 47: 1170-

1172 (1990).


415.[272]. SEEMAN, P.: Multiple D2 dopamine receptors. Clin. Neuropharmacol. 13: 124-125 (1990).


416.[273]. SEEMAN, P.: Dopamine receptors. In: Receptor data for Biological Experiments, edited by

H.N. Doods and J.C.A. Van Meel and H. Doods, Ellis Horwood Ltd., Chichester, 1991, pp.

42-46.


417.[274]. SEEMAN, P.: Elevated D2 in schizophrenia: Role of endogenous dopamine and cerebellum.

Neuropsycho-pharmacology 7: 55-57 (1992).


418.[275].  NIZNIK, H. B., FOGEL, E. F., FASSOS, F. F., and SEEMAN, P.: The dopamine transporter

is absent in Parkinsonian putamen and reduced in the caudate nucleus. J. Neurochem. 56: 192-

193 (1991).


419.[276]. SEEMAN, P.: Brain dopamine receptors (Citation Classic). Current Cont. Life Sci. 33 (Nos.

52-53): 13 (1990). 


420.[277]. SUNAHARA, R.K., NIZNIK, H.B., WEINER, D.M., STORMANN, T.M., BRANN, M.R.,

KENNEDY, J.L., GELERNTER, J.E., ROZMAHEL, R., YANG, Y., ISRAEL, Y.,

SEEMAN, P., and O'DOWD, B.F.:   Human dopamine D1 receptor encoded by an intronless

gene on chromosome 5. Nature 347: 80-83 (1990).


421.[278]. O'DOWD, B.F., NIZNIK, H.B., SUNAHARA, R., SEEMAN, P., and ISRAEL, Y.: Cloning

of a human receptor with amino acid sequence homology to the rat D2-dopamine receptor. In

"The Molecular Pathology of Alcoholism", NATO Adv. Study Inst., (1990).


422.[279]. WEINER, D.M., LEVEY, A.I., SUNAHARA, R.K., NIZNIK, H.B., O'DOWD, B.F.,

SEEMAN, P., and BRANN, M.R.: Dopamine D1 and D2 receptor mRNA in rat brain. Proc.

Nat. Acad. Sci., U.S.A. 88: 1859-1863 (1991).


423. SEEMAN, P.: Receptor density in vivo: Role of endogenous transmitter. Colleg. Int.

Neuropsychopharma-cologicum Abstr., p. 55 (1990).


424. SEEMAN, P.: Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and

receptor linkage. Amer. Coll. Neuropsychopharmacol. (Abstr.), 29th Meeting, p. 18 (1990).


425. SEEMAN, P.: Dopamine receptors in schizophrenia. Colleg. Int.

Neuropsychopharmacologicum Abstr. p. 42 (1990).


426.[280]. MENGOD, G., VILARO, M.T., NIZNIK, H.B., SUNAHARA, R.K., SEEMAN, P.,

O’DOWD, B.F., and PALACIOS, J.M.: Visualization of a dopamine D1 receptor mRNA in

human and rat brain. Mol. Brain Res. 10: 185-191 (1990).


427. SEEMAN, P.: Cloning of human dopamine receptor. Nature 347: 19 (1990). (News and

Views).


428.[281]. SEEMAN, P., and SCHAUS, J.: Dopamine receptors labelled by [3H]quinpirole. Eur. J.

Pharmacol. 203: 105-109 (1991).


429.[282]. SEEMAN, M.V., and SEEMAN, P.: Future schizophrenia medicines. In: The mental hospital

in the 21st century. Edited by E. Persad, S.S. Kazarian and L.W. Joseph. Wall & Emerson,

Inc., Toronto, 1992 pp. 168-172.


430.[283]. VAN TOL, H.H.M., BUNZOW, J.R., GUAN, H.-C., SUNAHARA, R.K., SEEMAN, P.,

NIZNIK, H.B., and CIVELLI, O.: Cloning of the gene for a human dopamine D4 receptor

with high affinity for the antipsychotic clozapine. Nature 350: 610-614 (1991). 


431.[284]. SUNAHARA, R.K., GUAN, H.-C., O’DOWD, B., SEEMAN, P., LAURIER, L.G., NG, G.,

GEORGE, S., TORCHIA, J., VAN TOL, H.H.M., and NIZNIK, H.B.: Cloning of the gene for

a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614-

619 (1991).


432.[285]. SEEMAN, P.: Receptor selectivities of atypical neuroleptics. In: Novel Antipsychotic Drugs,

edited by H.Y. Meltzer, Raven Press Ltd., New York, 1992, pp. 145-154.


433. SEEMAN, P.: Dopamine receptors and neuroleptics. In: Remoxipride - A New

Antipsychotic. Int. Mtng., 

Evian, France (1991).


434. KENNEDY, J.L., GELERNTER, J., GIUFFRA. L.A., NIZNIK, H.B., O’DOWD, B.F.,

SEEMAN, P., LEBEAU, M., CIVELLI, O., GRANDY, D.K., and KIDD, K.K.: The

dopamine D1 receptor gene maps to chromosome 5. Amer. Coll. Neuropsychopharmacol.

29th Meeting, p. 114 (1990) (Abstr.).


435.[286]. NIZNIK, H.B., SUNAHARA, R.K., VAN TOL, H.H.M.., SEEMAN, P., WEINER, D.M.,

STORMANN, T.M., BRANN, M.R., and O’DOWD, B.F.: The dopamine D1 receptor. In: G-

linked Receptors, edited by M.R. Brann (1991).


436. SEEMAN, P.: Dopamine receptors, clinical and basic. The Nucleus 69: p. 5. Abstr. in 730th

meeting of N.E. sect. Amer. Chem. Soc., Div. Med. Chem. (Jan. 1991).


437. GELERNTER, J., KENNEDY, J.L., O’DOWD, B.F., NIZNIK, H.B., SUNAHARA, R.,

SEEMAN, P., and KIDD, K.K.: Exclusion of close linkage of Tourette syndrome to D1

dopamine receptor. Amer. Psychiatr. Assn., Abstr. (1991).


438.[287]. NEUMEYER, J.L., BAINDUR, N., NIZNIK, H.B., GUAN, H.-C., and SEEMAN, P.: (±)-3-

Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, a new high

affinity D1 dopamine receptor ligand: Synthesis and structure-activity relationship. J. Med.

Chem. 34: 3366-3371 (1991).


439. O’DOWD, B.F., NGUYEN, T., JIN, H., GRUPP, L., and SEEMAN, P.: Two human

pseudogenes homologous to the D5-dopamine receptor. Soc. Neurosci. Abstr. 17: 599 (1991).

 

440.[288]. BAINDUR, N., TRAN, M., NIZNIK, H.B., GUAN, H.C., SEEMAN, P., and NEUMEYER,

J.L.: (±)3-Allyl-7-halo-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines as

selective high affinity D1 dopamine receptor antagonists: Synthesis and structure-activity

relationship. J. Med. Chem. 35: 67-72 (1992).


441.[289]. SEEMAN, P.: Cloned dopamine receptors: Targets in therapy of drug abuse. In: Molecular

Approaches to Drug Abuse Research. Vol. II, Nat. Inst. Drug Abuse Monograph 126. Edited

by T.N.H. Lee, U.S. Dept. Health Human Services. Nat. Inst. Drug Abuse (1992) pp. 35-47.


442.[290]. NGUYEN, T., JIN, H., TARUSCIO, D., WARD, D., KENNEDY, J.L., SEEMAN, P., and

O’DOWD, B.F.:  Human dopamine D5 receptor human pseudogenes. Gene 109: 211-218

(1991).


443.[291]. GEHLERT, D.R., GACKENHEIMER, S.L., SEEMAN, P., and SCHAUS, J.:

Autoradiographic localization of [3H]-quinpirole binding to D2 and D3 receptors in rat brain.

Eur. J. Pharmacol. 211: 189-194 (1992).


444.[292]. NGUYEN, T., SUNAHARA, R., VAN TOL, H.H.M., SEEMAN, P., and O’DOWD, B.F.:

Transcription of a human dopamine D5 pseudogene. Biochem. Biophys. Res. Commun. 181:

16-21 (1991).


445.[293]. OHARA, K., ULPIAN, C., SEEMAN, P., SUNAHARA, R.K., VAN TOL, H.H.M., and

NIZNIK, H.B.:  Schizophrenia: Dopamine D1 receptor sequence is normal, but has DNA

polymorphisms. Neuropsychopharmacology 8: 131-135 (1993).


446.[294]. SEEMAN, P., OHARA, K., ULPIAN, C., SEEMAN, M.V., JELLINGER, K., VAN TOL,

H.H.M., and NIZNIK, H.B.: Schizophrenia: Normal sequence in the dopamine D2 receptor

region which couples to G proteins. DNA polymorphisms in D2. Neuropsychopharmacology

8: 137-142 (1993).


447. SEEMAN, P.: Dopamine receptors and neuroleptics. 30th meeting Amer. Coll.

Neuropsychopharmacol. p. 39 (1991).


448.[295]. GELERNTER, J., KENNEDY, J.L., GRANDY, D.K., ZHOU, Q.-Y., CIVELLI, O., PAULS,

D.L., PAKSTIS, A., KURLAN, R., SUNAHARA, R.K., NIZNIK, H.B., O’DOWD, B.,

SEEMAN, P., and KIDD, K.K.:  Exclusion of close linkage of Tourette’s syndrome to D1

dopamine receptor. Am. J. Psychiat. 150: 449-453 (1993). 


449. GEHLERT, D.R., GACKENHEIMER, S.L., SEEMAN, P., and SCHAUS, J.M.: Localization

of 3H-quinpirole binding to D-2 and D-3 receptors in rat brain. Soc. Neurosci. Abstr. 17: 820

(1991).


450.[296]. DEMCHYSHYN, L., SUNAHARA, R.K., MILLER, K., TEITLER, M., HOFFMAN, B.J.,

KENNEDY, J.L., SEEMAN, P., VAN TOL, H.H.M., and NIZNIK, H.B.: A human serotonin

1D receptor variant (5HT1Dß) encoded by an intronless gene on chromosome 6. Proc. Nat.

Acad. Sci., U.S.A. 89: 5522-5526 (1992).


451. MARCHESE, A., NGUYEN, T., WEINSHANK, R., BARD, J., JIN, H., SEEMAN, P., and

O’DOWD, B.F.: D5-dopamine receptor genes: A recent duplication in the G-protein linked

receptor gene family. FASEB J. 6: A1555 (Abstr. 3587) (1992).


452. MARCHESE, A., NGUYEN, T., MADRAS, B., SEEMAN, P., and O’DOWD, B.F.: D5-

dopamine receptor pseudogenes. Canad. Fed. Biol. Soc. (Abstr.) (1992).


453.[297]. SUNAHARA, R., SEEMAN, P., VAN TOL, H.H.M, and NIZNIK, H.B.: Dopamine

receptors and antipsychotic drug response. Brit. J. Psychiat. 163 (Suppl. 22): 31-38 (1993).


454. GEHLERT, D.R., SEEMAN, P., and SCHAUS, J.M.: 3H-Quinpirole binds to D-2 and D-3

receptors in the rat brain.  In: Dopamine ‘92. From Neurobiology to Neuropathology. (Abstr.)

(1992).


455.[298]. SEEMAN, P.: Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2,

clozapine occupies D4. Neuropsychopharmacology 7: 261-284 (1992).


456.[299]. SEEMAN, P., GUAN, H.-C., CIVELLI, O., VAN TOL, H.H.M., SUNAHARA, R.K., and

NIZNIK, H.B.;  The cloned dopamine D2 receptor reveals different densities for dopamine

antagonist ligands. Implications for human brain positron emission tomography. Eur. J.

Pharmacol., Mol. Pharmacol. Sect. 227: 139-146 (1992).


457.[300] LAROSA, G., ARMSTRONG, P.W., SEEMAN, P., and FORSTER, C.: ß Adrenoceptor

recovery after heart failure in the dog. Cardiovascular Res. 27: 489-493 (1993).


458.[301] VAN TOL, H.H.M., WU, C.M., GUAN, H.-C., OHARA, K., BUNZOW, J.R., CIVELLI, O.,

KENNEDY, J., SEEMAN, P., NIZNIK, H.B., and JOVANOVIC, V.: Multiple dopamine D4

receptor variants in the human population. Nature 358: 149-152 (1992).


459. SEEMAN, P.: Clozapine and dopamine receptors. Canad. Psychiatr. Assn. (Abstr.)(Montreal,

Sept. 1992).


460. MARCHESE, A., BEISCHLAG, T., NGUYEN, T., NIZNIK, H., GRUPP, L., SEEMAN, P.,

and O’DOWD, B.F.: ALU repeat involved in the duplication of the human D5-dopamine

receptor gene. Soc. Neurosci. Abstr. 18: 275 (1992).


461. SUGAMORI, K.S., SUNAHARA, R.K., GUAN, H.C., BULLOCH, A.G.M., SEEMAN, P.,

KISH, S.J., NIZNIK, H.B., and VAN TOL, H.H.M.: Cloning and characterization of a

serotonin receptor from LYMNEA STAGNALIS. Soc. Neurosci. Abstr. 18: 462 (1992).


462. MUKHERJEE, T., SEEMAN, P., and GEORGE, S.R.: Intrastriatal reserpine administration

decreases dopamine receptor mRNA levels in rat striatum. Soc. Neurosci. Abstr. 18: 276

(1992).


463. VAN TOL, H.H.M., WU, C.M., GUAN, H.-C., OHARA, K., BUNZOW, J.R., CIVELLI, O.,

KENNEDY, J., SEEMAN, P., NIZNIK, H.B., and JOVANOVIC, V.: Allelic variation of the

human D4 receptor. Soc. Neurosci. Abstr. 18: 7 (1992).


464. DEMCHYSHYN, L.L., CORNESS, J., SUNAHARA, R.K., SEEMAN, P., VAN TOL,

H.H.M., SRIKANT, C.B., PATEL, Y.C., and NIZNIK, H.B.: Molecular cloning and

characterization of four members of the somatostatin receptor gene family. Soc. Neurosci.

Abstr. 18: 449 (1992). 


465. BEISCHLAG, T.V., TIRPAK, A.E., SUNAHARA, R.K., VAN TOL, H.H.M., SEEMAN, P.,

and NIZNIK, H.B.: Molecular cloning and characterization of the 5’-flanking region and

promotor of the human dopamine D5 receptor gene. Soc. Neurosci. Abstr. 18: 275 (1992).


466.[302] MENGOD, G., VILLARO, M.T., LANDWEHRMEYER, G.B., MARTINEZMIR, M.I.,

NIZNIK, H.B., SUNAHARA, R.K., SEEMAN, P., ODOWD, B.F., PROBST, A. and

PALACIOS, J.M.: Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and

rat brain. Neurochem. Int. 20 (Suppl.): 33S-43S (1992).


467.[303]. SUGAMORI, K.S., SUNAHARA, R.K., GUAN, H.-C., BULLOCH, A.G.M., TENSEN, C.P., 

SEEMAN, P., NIZNIK, H.B., and VAN TOL, H.H.M.: Serotonin receptor cDNA cloned

from Lymnea stagnalis. Proc. Nat. Acad. Sci., U.S.A. 90: 11-15 (1993).


468. SEEMAN, P.: Schizophrenia, antipsychotic drugs, and clozapine. Schizophrenia Int. Symp.

(Vancouver, July 1992).


469.[304]. CORNESS, J., DEMCHYSHYN, L.L., SEEMAN, P., VAN TOL, H.H.M., SRIKANT, C.B.,

KENT, G., PATEL, Y.C., and NIZNIK, H.B.: A human somatostatin receptor (SSTR 3),

located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides.

FEBS Letts. 321: 279-284 (1993).


470.[305]. SEEMAN, P.: Schizophrenia as a brain disease: The dopamine receptor story. Arch. Neurol.

50: 1093-1096 (1993).


471.[306]. SEEMAN, P., GUAN, H.-C., VAN TOL, H.H.M., and NIZNIK, H.B.: Low density of

dopamine D4 receptors in Parkinson’s, schizophrenia and control brain striata. Synapse 14:

247-253 (1993).


472.[307]. SEEMAN, P., ULPIAN, C., LARSEN, R.D., and ANDERSON, P.S.: Dopamine receptors

labelled by PHNO. Synapse 14: 254-262 (1993).


473. WONG, D.T., MOORE, N.A., CALLIGARO, D.O., BYMASTER, F., and SEEMAN, P.:

The preclinical pharmacology of olanzapine, a novel antipsychotic. Int. Congr. Psychiat.

(1992).


474.[308]. O’DOWD, B.F., SEEMAN , P., and GEORGE, S.R.: Dopamine Receptors. In: Handbook of

Receptors and Channels, G Protein-coupled Receptors, edited by S.J. Peroutka. CRC Press

Inc., Boca Raton, Florida, 1994, pp. 95-123. 


475.[309]. SEEMAN, P.: Dopamine receptors in schizophrenia. In: Dopamine Receptors, edited by H.B.

Niznik.  Marcel Dekker, Inc., New York, 1993, pp. 541-549.


477.[310]. TOMIC, M., SEEMAN, P., GEORGE, S.R., and O’DOWD, B.F.: Dopamine D1 receptor

mutagenesis: Biochem. Biophys. Res. Commun. 191: 1020-1027 (1993). 


478.[311]. SEEMAN, P., GUAN, H.-C. and VAN TOL, H.H.M.: Dopamine D4 receptors elevated in

schizophrenia. Nature 365: 441-445 (1993).


479.[312]. SEEMAN, P., and VAN TOL, H.H.M.: Dopamine D4 receptors bind inactive (+)-aporphines,

suggesting neuroleptic role.  Sulpiride not stereoselective.  Eur. J. Pharmacol. 233: 173-174

(1993).


480.[313]. SEEMAN, P.: Dopamine Receptors, Clinical correlates. In: Neuropsychopharmacology: The

Fourth Generation of Progress. Edited by F. E. Bloom and D. J. Kupfer, Raven Press, New

York, 1995, pp. 295-302.


481.[314]. SEEMAN, P., and VAN TOL, H.H.M.: Dopamine Receptor Pharmacology. Curr. Opinion

Neurol. Neurosurg. 6: 602-608 (1993).


482. SEEMAN, P.:  Schizophrenia, antipsychotic drugs and D4. Neuropsychopharmacology 9:

13S-14S (1993).


483.[315]. SEEMAN, P., SUNAHARA, R.K., and NIZNIK, H.B.: Receptor-receptor link in membranes

revealed by ligand competition: Example for dopamine D1 and D2 receptors. Synapse 17: 62-

64 (1994).


484.[316]. DASILVA, J.N., WILSON, A.A., SEEMAN, P., and HOULE, S.: Synthesis of [11C]SKF

75670 as a potential dopamine D1 receptor agonist imaging agent for PET.  J. Label. Compd.

Radiopharm. 35: 460-461 (1994).


485.[317]. SEEMAN, P., and VAN TOL, H.H.M.: Dopamine receptor pharmacology. Trends in

Pharmacolog. Sci. 15: 264-270 (1994). 


486.[318]. DEMCHYSHYN, L.L., SRIKANT, C.B., SUNAHARA, R.K., KENT, G., SEEMAN, P.,

VAN TOL, H.H.M., PANETTA, R., PATEL, Y.C., and NIZNIK, H.B.: Cloning and

expression of a human somatostatin-14-selective receptor variant (Somatostatin receptor 4)

located on chromosome 20. Mol. Pharmacol. 43: 894-901 (1993).


487.[319]. SEEMAN, P., and VAN TOL, H.H.M.: Deriving the therapeutic concentrations for clozapine

and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or

D4 receptor varies with the affinity of the competing radioligand. Eur. J. Pharmacol. - Mol.

Pharmacol. Section 291: 59-66 (1995).


488.[320]. NOBREGA, J.N., and SEEMAN, P.: Dopamine D2 receptors mapped in rat brain with

[3H](+)PHNO. Synapse 17: 167-172 (1994).


489.[321]. PHILLIPS, S.T., DE PAULIS, T., BARRON, B.M., SIEGEL, B.W., SEEMAN, P., VAN

TOL, H.H.M., GUAN, H.-C., and SMITH, H.E.: Binding of 5H-dibenzo[b,e][1,4]diazepine

and chiral 5H-dibenzo[a,d]cyclo-heptene analogues of clozapine to dopamine and serotonin

receptors. J. Med. Chem. 37: 2686-2696 (1994).


490. SEEMAN, P: Dopamine Receptors: Basic and Clinical. Jap. J. Pharmacol. 64 (Suppl. I): p.

5P (1994).


491.[322]. SEEMAN, P, ULPIAN, C., CHOUINARD, G., VAN TOL, H.H.M., DWOSH, H.,

LIEBERMAN, J.A., SIMINOVITCH, K., LIU, I.S.C., WAYE, J., VORUGANTI, P.,

HUDSON, C., SERJEANT, G.R., MASIBAY, A.S., and SEEMAN, M.V.: Dopamine D4

receptor variant, D4GLYCINE194, in Africans, but not in Caucasians. No association with

schizophrenia. Amer. J. Med. Gen. (Neuropsychiatric Genet.): 54: 384-390 (1994).


492. SUNAHARA, R.K., NIZNIK, H.B., and SEEMAN, P.: Dopamine D1-D2 receptor crosstalk

is mediated by G-proteins: Implications for the bg-subunits. Abstr. Amer. College

Neuropsychopharmacol. 32: p. 25 (1993).


493. SCHOOTS, O., YUE, K.-T., HAMPSON, D.R., MACDONALD, J.F., SEEMAN, P., and

VAN TOL, H.H.M.: Cloning and expression of a human G-protein activated potassium

channel from cerebellum. Soc. Neurosci. Abstr. 20: 75 (1994).


494.[323]. BYMASTER, F.P., CALLIGARO, D.O., FALCONE, J.F., MARSH, R.D., MOORE, N.A.,

TYE, N.C., SEEMAN, P., and WONG, D.T.: Radioreceptor binding profile of the atypical

antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96 (1996).


495. SEEMAN, P.,: Schizophrenia and dopamine receptors. J. Psychopharmacol.: p. A43, Abstr.

169 (1994).


496.[324]. SCHOOTS, O., SEEMAN, P., GUAN, H.-C., PATERSON, A., and VAN TOL, H.H.M.:

Long-term haloperidol elevates dopamine D4 receptors by two-fold in rats. Eur. J.

Pharmacol., Mol. Pharmacol. Section 289: 67-72 (1995).


497.[325]. BEISCHLAG, T.V., MARCHESE, A., MEADOR-WOODRUFF, J.H, DAMASK, S.P.,

O’DOWD, B.F., TYNDALE, R.F., VAN TOL, H.H.M., SEEMAN, P., and NIZNIK, H.B.:

The human dopamine D5 receptor: Cloning and characterization of the 5’-flanking and

promoter region. Biochemistry 34: 5960-5970 (1995).


498.[326]. SEEMAN, P.: Therapeutic receptor-blocking concentrations of neuroleptics. Int.  Clin.

Psychopharmacol. 10 (Suppl. 3): 5-13 (1995).


499.[327]. PHILLIPS, S.T., DE PAULIS, T., NEERGAARD, J.R., BARON, B.M., SIEGEL, B.W.,

SEEMAN, P., VAN TOL, H.H.M., GUAN, H.-C., and SMITH, H.E.: Binding of 5H-

dibenzo[a,d]cycloheptene and dibenzo[b,f]oxepin analogues of clozapine to dopamine and

serotonin receptors. J. Med. Chem. 38: 708-714 (1995).


500.[328]. SEEMAN, P., and VAN TOL, H.H.M.: Dopamine D4-like receptor elevation in

schizophrenia: Cloned D2 and D4 receptors cannot be discriminated by raclopride

competition against [3H]nemonapride. J. Neurochem. 64: 1413-1415 (1995).


501. BEISCHLAG, T.V., MEADOR-WOODRUFF, J.H., MARCHESE, A., O’DOWD, B.F.,

VAN TOL, H.H.M., SEEMAN, P., and NIZNIK, H.B.: Analysis of the human dopamine D5

receptor gene 5’-region and D5 mRNA distribution in human brain. Soc. Neurosci. Abstr. 20:

909 (1994).


502.[329]. LIU, I.S.C., SEEMAN, P., SANYAL, S., ULPIAN, C., RODGERS-JOHNSON, P.E.B.,

SERJEANT, G.R., and VAN TOL, H.H.M.: The dopamine D4 receptor variant in Africans,

D4Valine194Glycine, is insensitive to dopamine and clozapine. Report of a homozygous

individual. Amer. J. Med. Gen. 61: 277-282 (1996).


503.[330]. SCHWARTZ, J.-C., CARLSSON, A., CARON, M., SCATTON, B., CIVELLI, O.,

KEBABIAN, J.W., LANGER, S.Z, SEDVALL, G., SEEMAN, P., SPANO, P.F.,

SOKOLOFF, P., and VAN TOL, H.H.M.: Dopamine receptors. IUPHAR Compendium of

Receptor Characterization and Classification, 2nd edition, IUPHAR (2000), pp. 171-181.


504.[331]. SEEMAN, P., GUAN, H.-C., NOBREGA, J., JIWA, D., MARKSTEIN, R., BALK, J.-H.,

PICETTI, R.,  BORELLI, E., and VAN TOL, H.H.M.: Dopamine D2-like sites in

schizophrenia, but not in Huntington’s, Alzheimer’s or control brains, for [3H]benzquinoline.

Synapse 25: 137-146 (1997).


505.[332]. SEEMAN, P.: Dopamine receptors as new targets for novel drugs. Current Approaches to

Psychoses: Diagnosis and Management, 4: 8-9. Edited by S.R. Marder, Excerpta Medica,

Princeton, April 1995.


506.[333]. SEEMAN, P.: Dopamine receptors and psychosis. [Scientific American] Science and

Medicine 2(5): 28-37, (Sept.-Oct., 1995).


507.[334]. SEEMAN, P., GUAN, H.-C., and VAN TOL, H.H.M.: Schizophrenia: Elevation of dopamine

D4-like sites, using [3H]nemonapride and [125I]epidepride. Eur. J. Pharmacol. 286: R3-R5

(1995).


508. MARCHESE, A., NGUYEN, T., JUNG, B.P., SHEN, Y., SALDIVIA, V.R., SEEMAN, P.,

GEORGE, S.R., and O’DOWD, B.: Cloning of receptor genes that share identity with peptide

binding GPCR genes. Soc. Neurosci. Abstr. 21: 1596 (1995).


509.[335]. BEISCHLAG, T.V., NAM, D., ULPIAN, C., SEEMAN, P., and NIZNIK, H.B.: A

polymorphic dinucleotide repeat in the human dopamine D5 receptor gene promoter.

Neurosci. Letts. 205: 173-176 (1996).


510. VAN TOL, H.H.M., SEEMAN, P., LIU, I., SANYAL, S., ASGHARI, V., OLDENHOF, J.,

KNAPP, M., and SCHOOTS, O.: Structure-function studies at the human D4 receptor. Amer.

College Neuropsychopharmacol. (Abstr.) (1995).


511. SEEMAN, P., and VAN TOL, H.H.M.: Antipsychotics block D2 and D4. New site in

schizophrenia. Amer. Psychiatr. Assn. (New York), Abstracts. (1996).


512. SEEMAN, P., and VAN TOL, H.H.M.: Dopamine D4 receptors in schizophrenia? Reply. J.

Neurochem. 66: 882-883 (1996).


513. SEEMAN, P., and VAN TOL, H.H.M.: Therapeutic receptor-blocking concentrations of

neuroleptics. Schizophrenia Res. 18: 142-143 (1996).


514. SEEMAN, P., and VAN TOL, H.H.M.: D4 receptors and schizophrenia. J. Neurochem. 65:

2382-2383 (1995).


515.[336]. SEEMAN, P., CORBETT, R., and VAN TOL, H.H.M.: Atypical neuroleptics have low

affinity for dopamine D2 receptors or are selective for D4. Neuropsychopharmacology 16: 93-

110 and 16: 127-135 (1997).


516.[337]. SEEMAN, P., CORBETT, R., NAM, D., and VAN TOL, H.H.M.: Dopamine and serotonin

receptors: Amino acid sequences, and clinical role in neuroleptic Parkinsonism. Jpn. J.

Pharmacol. 71: 187-204 (1996).


517.[339]. SEEMAN, P., and KAPUR, S.: Clozapine occupies high levels of dopamine D2 receptors.

Life Sci. 60: 207-216 (1997).


518.[340]. SEEMAN, P.: Clozapine withdrawal: serotonergic or dopaminergic mechanisms? Arch Gen.

Psychiatry 54: 762-763 (1997).


519. BOV, C., KLIMKE, A., HOLSCHBACH, M., HERZOG, H., ROTA-KOPS, E.,

MÜHLENSIEPEN, H., SONNENBERG, F., WUNDERLICH, G., SEEMAN, P., VAN TOL,

H.H.M., MARKSTEIN, R., GAEBEL, W., STÖCKLIN, G., and MÜLLER-GÄRTNER,

H.W.: Dopamine-D4 receptors in the living primate brain. Soc. Nucl. Med., 43rd Mtng,

Abstract (1996).


520.[341]. SEEMAN, P., CORBETT, R., and VAN TOL, H.H.M.: Dopamine D4 receptors may

alleviate antipsychotic-induced Parkinsonism. Adv. Pharmacol. 42: 478-482 (1997).

[Catecholamines, edited by Goldstein, D.S., Eisenhofer, G., and McCarty, R., Academic

Press, San Diego, 1997). (Eighth Int. Catecholamine Symp. , Asilomar, USA).


521.[342]. QIAN, I.H-P., KUSUMI, I., ULPIAN, C., TALLERICO, T., NAM, D., LIU, I., SEEMAN,

M.V., and SEEMAN, P.: A human serotonin-7 receptor pseudogene. Mol. Brain Res. 53:

339-343 (1998).


522.[343]. SEEMAN, P., TALLERICO, T., CORBETT, R., VAN TOL, H.H.M., and KAMBOJ, R.K.:

Commentary: Role of dopamine D2, D4, and serotonin 2A receptors in antipsychotic action

and anticataleptic action. J. Psychopharmacol. 11: 15-17 (1997).


523. SEEMAN, P.: Schizophrenia and dopamine receptors. 19th Mtng. Can. College

Neuropsychopharmacol. (Abstr.) p. 2 (1996).


524.[344]. NG, G., O’DOWD, B.F., LEE, S.P., CHUNG, H.T., BRANN, M.R., SEEMAN, P., and

GEORGE, S.R.: Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem.

Biophys. Res. Commun. 227: 200-204 (1996). 


525. SEEMAN, P.: Olanzapine blocks type 2 and type 4 dopamine receptors. 4th Int. Conf. on

Schizophrenia, Vancouver. Abstr. (Oct. 6, 1996).


526. LEE, S.P., G.Y.K. NG, ZAWARYNSKI, P., SEEMAN, P., O’DOWD, B.F., and GEORGE,

S.R.: Regulation of the dopamine D2 receptor dimer. Soc. Neurosci. Abstr. 23: 1780 (1997).


527.[345]. SEEMAN, P.: Opening the dopamine D4 door. NeuroReport 7: R1-R2 (1996).


528.[346]. SEEMAN, P.: Schizophrenia and brain dopamine receptors. J. California Alliance Mentally

Ill. 7: 23-25 (1996).


529. SEEMAN, P.: Neurobiology of dopamine receptors, antipsychotic drugs and schizophrenia.

Biol. Psychiat. 42: 198S-199S (1997). 


530.[347] SEEMAN, P.: Dopamine receptors - Clinical correlates. In: Psychopharmacology: The

Fourth Generation of Progress. CD ROM edited by S.J. Watson, F.E. Bloom and D.J. Kupfer,

Lippincott-Raven, Hagerstown, MD, 1998.


531. SEEMAN, P.: Antipsychotics block type 2 and type 4 dopamine receptors. Am. Chem. Soc.

Div. Med. Chem. Abstr. 158 (San Francisco) (1997).


532.[348]. NAM, D., QIAN, I.H.-P., KUSUMI, I., ULPIAN, C., TALLERICO, T., LIU, I.S.C., and

SEEMAN, P.: The human serotonin-7 receptor pseudogene: variation and chromosome

location. J. Psychiat. Neurosci. 23: 214-216 (1998).


533.[349].  LIU, I.S.C., KUSUMI, I., ULPIAN, C., TALLERICO, T., and SEEMAN, P.: A serotonin-4-

receptor-like pseudogene in humans. Mol. Brain Res. 53: 98-103 (1998).


534.[350]. SEEMAN, P., and TALLERICO, T.: Antipsychotic drugs which elicit little or no

Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels

of these receptors. Mol. Psychiat. 3: 123-134 (1998). 


535.[351]. SEEMAN, P., and MADRAS, B.K.: Anti-hyperactivity medication: methylphenidate and

amphetamine. Mol. Psychiat. 3: 386-396 (1998).


536. SEEMAN, P.: Dopamine receptors and antipsychotic drugs. Dutch Pharmacolog. Soc. (in

Lunteren, The Netherlands; The E. Ariens Award Lecture). (Feb. 20, 1997) (Abstract)


537. SEEMAN, P.: Dopamine receptors and antipsychotic drugs - What makes them atypical?

Canad. Psychiatr. Assoc. (Sept. 1997) (Abstract) 


538. SEEMAN, P.: Dopamine receptors and antipsychotic drugs. Int. Fed. Pharmacy Mtng. (Aug.

31, 1997, Vancouver) (Abstract), p. 10. 


539. ZAWARYNSKI, P., LEE, S.P., TALLERICO, T., NG, G.Y.K., SEEMAN, P., O’DOWD,

B.F.,  REMINGTON, G., and GEORGE, S.R.: Separation of dopamine D2 receptor

monomers and dimers. Soc. Neurosci. Abstr. 23: 1780 (1997).


540.[352]. NG, G.Y.K., VARGHESE, G., CHUNG, H.T., TROGADIS, J., SEEMAN, P., O’DOWD,

B.F., and GEORGE, S.R.: Resistance of the dopamine D2L receptor to desensitization

accompanies the up-regulation of receptors on to the surface of Sf9 cells. Endocrinology 138:

4199-4206 (1997).


541.[353]. SEEMAN, P.: Comment on “Positron emission tomography finding of a high striatal D2

receptor occupancy in olanzapine-treated patients.”, by A.-L. Nordström, S. Nyberg, H.

Olsson and L. Farde. Arch. Gen. Psychiat. 55: 284 (1998).


542. SEEMAN, N., and SEEMAN, P.: Don’t legalize medical marijuana. Toronto Star, Monday,

Jan. 5, 1998, p. A14. 


543.[354]. SEEMAN, P., and TAMMINGA, C.: Pruning during development. Am. J. Psychiat. 156: 168

(1999).


544. SEEMAN, P.: Dopamine Receptors. In: The molecular function and pathophysiology of the

dopaminergic neuron. Kagoshima Int. Symp., Japan (Oct. 1997). (Abstract).


545. SEEMAN, P.: Schizophrenia, dopamine receptors and antipsychotic drugs. 151st Annual

Meeting, Amer. Psychiatric Assn., 151st Meeting: pp. 339-340 (Toronto, June 2, 1998)

(Abstract).


546. GEORGE, S.R., VARGHESE, G., LEE, S.P., ZEMAN, P.R., SEEMAN, P., NG, G.Y.K., and

O’DOWD, B.F.: A transmembrane domain-derived peptide inhibits dopamine D1 receptor

function without affecting receptor oligomerization. Soc. Neurosci. Abstr. 24: p. 1358 (1998). 


547. KAPUR, S., SEEMAN, P., JOYCE, J., LARUELLE, M., and BRIER, A.: The dopamine

hypothesis of schizophrenia - Alive, well, and moving ahead. Biol. Psychiat. 43: 75S (1998)

(Abstract).


548.[355]. SEEMAN, P., and TALLERICO, T.: Rapid release of antipsychotic drugs from dopamine D2

receptors: An explanation for low receptor occupancy and early clinical relapse upon drug

withdrawal of clozapine or quetiapine. Amer. J. Psychiat. 156: 876-884 (1999).


549.[356]. ZAWARYNSKI, P., TALLERICO, T., SEEMAN, P., LEE, S.P., O’DOWD, B.F., amd

GEORGE, S.R.: Dopamine D2 receptor dimers in human and rat brain. FEBS Letts. 441: 383-

386 (1998).


550.[357]. GEORGE, S.R., LEE, S.P., VARGHESE, G., ZEMAN, P.R., SEEMAN, P., NG, G.Y.K., and

O’DOWD, B.F.: A transmembrane domain-derived peptide inhibits D1 dopamine receptor

function without affecting receptor oligomerization. J. Biol. Chem. 273: 30244-30248 (1998). 


551.[358]. FITZGERALD, P., KAPUR, S., and SEEMAN, P.: Neuroreceptor Studies in Psychotic

Disorders in the Elderly: Potential for Understanding Antipsychotic Effects. In: Late Onset

Schizophrenia. Edited by R. Howard, P.V. Rabins, and D.J. Castle, Wrightson Biomedical

Publishing Ltd., Petersfield, U.K. (1999) pp. 205-214.


552.[359]. SEEMAN, P.: Antipsychotic drugs, dopamine receptors, and schizophrenia. Clin. Neurosci.

Res. 1: 53-60 (2001).


553.[360]. SEEMAN, P.: Antipsychotic drugs, dopamine receptors, and schizophrenia. In:

Neurotransmitter receptors in actions of antipsychotic medications, edited by M.S. Lidow,

CRC Press LLC, Philadelphia, 2000, pp. 43-63.


554.[361]. SEEMAN, P., NAM, D., ULPIAN, C., LIU, I.S.C., and TALLERICO, T.: A new dopamine

receptor, D2Longer, with a unique TG splice site, in human brain. Mol. Brain Res. 76: 132-

141 (2000).


555.[362]. SEEMAN, P., and KAPUR, S.: Olanzapine binding to dopamine receptors in vitro and in

vivo. in: Olanzapine (Zyprexa) — A Novel Antipsychotic. Edited by Tran, P.V., Bymaster,

F., Tye, N., Herrera, J., Breier, A., and Tollefson, G., Eli Lilly & Co., Lippincott Williams &

Wilkins, Philadelphia, 2000, pp. 3-24.


556.[363]. SEEMAN, P.,  and KAPUR, S.: The dopamine receptor basis of psychosis. in: Current issues

in the Psychopharmacology of Schizophrenia. Edited by Breier, A., Tran, P.V., Herrera, J.,

Bymaster, F., and Tollefson, G., Eli Lilly & Co., Lippincott Williams & Wilkins,

Philadelphia, 2001, pp. 73-84.


557. SILVESTRI, S., SEEMAN, M.V., NEGRETE, J.C., HOULE, S., SHAMMI, C.M.,

REMINGTON, G.J., KAPUR, S., ZIPURSKY, R.B., WILSON, A., CHRISTENSEN, B.K.,

and SEEMAN, P.: Dopamine D2 upregulation and 5HT2 downregulation measured after

neuroleptic withdrawal using PET. Schizophrenia Res. 36: 247 (1999).


558.[364]. WADENBERG, M.-L., and SEEMAN, P.: Clozapine pretreatment enhances raclopride

catalepsy. Eur. J. Pharmacol. 377: R1-R2 (1999).


559. SILVESTRI, S., WADENBERG, M.-L., and SEEMAN, P.: Cataleptic intensity predicts the

extent of dopamine D2 receptor up-regulation following low-dose administration of

haloperidol. Soc. Neurosci. Abstr. 25: 1054 (1999).


560. KARASINSKA, J.M., GEORGE, S.R., EL-GHUNDI, M., FLETCHER, P.J., SEEMAN, P.,

and O’DOWD,B.F.: Generation and behavioural characterization of mice lacking both the D1

and D3 dopamine receptors. Soc. Neurosci. Abstr. 25: 1470 (1999).


561.[365]. KAPUR, S., ZIPURSKY, R., JONES, C., SHAMMI, C.S., REMINGTON, G., and

SEEMAN, P.: A positron emission tomography study of quetiapine in schizophrenia - A

preliminary finding of an antipsychotic effect with only transiently high dopamine D2

receptor occupancy. Arch. Gen. Psychiat. 57: 553-559 (2000).


562.[366]. KAPUR, S., and SEEMAN, P.: Antipsychotic agents differ in how fast they come off the

dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiat. Neurosci.

25: 161-166 (2000).


563.[367]. SILVESTRI, S., SEEMAN, M.V., NEGRETE, J.-C., HOULE, S., SHAMMI, C.M.,

REMINGTON, G.J., KAPUR, S., ZIPURSKY, R.B., WILSON, A.A., CHRISTENSEN, B.K.,

and SEEMAN, P.: Increased dopamine D2 receptor binding following long-term treatment

with antipsychotics in humans: A clinical PET study. Psychopharmacology 152: 174-180

(2000).


565.[369]. KAPUR, S., and SEEMAN, P.: Does Fast Dissociation From the Dopamine D2 receptor

Explain the Action of Atypical Antipsychotics? - A New Hypothesis. Am. J. Psychiat. 158:

360-369 (2001).


566. KAPUR, S., and SEEMAN, P.: Transient occupancy at the D2 receptor - A new hypothesis

for atypical antipsychotics. Soc. Bol. Psychiat. (June, 2000; Chicago). Abstract.


567.[370]. LIU, I.S.C., GEORGE, S.R., and SEEMAN, P.: The dopamine D2Longer receptor has a

high-affinity state and inhibits adenylate cyclase. Mol. Brain Res. 77: 281-284 (2000).


568. SEEMAN, P., and KAPUR, S.: Atypical anti-psychotics have lower affinity than dopamine

for D2 receptors, and thus their D2 occupancy is brief. Brit. J. Clin. Pharmacol. (4th Congr.

Eur. Assoc. Clin. Pharmacol. Therap. Abstract 257, p. 68 (2000).


569.[371]. LEE, D.K., LYNCH, K.R., NGUYEN, T., IM, D.-S., CHENG, R., SALDIVA, V.R., LIU, Y.,

HENG, H.H.Q., SEEMAN, P., GEORGE, S.R., O’DOWD, B.F., and MARCHESE, A.:

Cloning and characterization of additional members of the G protein-coupled receptor family.

Biochim. Biophys. Acta 1490: 311-323 (2000).   


570. KAPUR, S., and SEEMAN, P.: Fast Koff at the dopamine D2 receptor (not high affinity at

other receptors) is the key to clozapine’s uniqueness and for atypical antipsychotic activity.

College Int. Neuropsychopharmacol. (Brussels) (July, 2000) (Abstract).


571.[372]. SEEMAN, P., and KAPUR, S.: Schizophrenia: More dopamine, more D2 receptors. Proc.

Nat. Acad. Sci. U.S.A. 97: 7673-7675 (2000).


572. KAPUR, S., WADENBERG. M.-L., McLELLAND, R., BARSOUM, S., BAKER, G.,

ZIPURSKY, R., and SEEMAN, P.: A low affinity at D2 receptor, NOT a high affinity at

other receptors (5HT2, D3, D4) is the reason why clozapine is an atypical antipsychotic. Soc.

Neurosci. Abstr. 26: (2000).


573.[373]. BINKLEY, K., KING, N., POONAI, N., SEEMAN, P., ULPIAN, C., and KENNEDY, J.:

Idiopathic Environmental Intolerance: Increased prevalence of panic-disorder-associated

cholecystokinin B receptor allele 7. J. Allergy Clin. Immunol. 107: 887-890 (2001). 


574.[374]. TALLERICO, T., NOVAK, G., LIU, I.S.C., ULPIAN, C., and SEEMAN, P.: Schizophrenia:

Elevated mRNA for dopamine D2Longer receptors in frontal cortex. Mol. Brain Res. 87: 160-

165  (2001).


575.[375]. NOVAK, G., SEEMAN, P., and TALLERICO, T.: Schizophrenia: elevated mRNA for

calcium-calmodulin-dependent protein kinase IIb in frontal cortex. Mol. Brain Res. 82: 95-

100 (2000).


576. SEEMAN, P.: Schizophrenia. In: Essential Science Indicators, edited by Jennifer Minnick,

Inst. Sci. Info., Philadelphia (Nov., 2001).


578. REMINGTON, G., KAPUR, S., SHAMMI, S., and SEEMAN, P.: ‘Extended’ dosing as an

alternative to ‘intermittent’ or ‘targeted’ antipsychotic therapy: Rationale and pilot study.

Schizophrenia Res. 49 (1-2, supplement): p. 243 (2001).


579. KAPUR, S., SEEMAN, P., ZIPURSKY, R., and REMINGTON, G.J.: Fast dissociation from

the dopamine D2 receptor (not high affinity at multiple receptors) is the key to “atypical”

antipsychotics. Schizophrenia Res. 49 (1-2, supplement): p. 92 (2001).


580.[377]. KAPUR, S., BARSOUM, S.C., and SEEMAN, P.: Dopamine D2 blockade by haloperidol:

3

H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology 23:

595-598 (2000). 


581.[378]. KAPUR, S., and SEEMAN, P.: Ketamine has equal affinity for NMDA receptors and the

high-affinity state of the dopamine D2 receptor. Biol. Psychiatry 49: 954-957 (2001).


582.[379]. KAPUR, S., and SEEMAN, P.: NMDA antagonists ketamine and PCP have direct effects on

the dopamine D2 and serotonin 5-HT2 receptors - implications for models of schizophrenia.

Mol. Psychiat. 7: 837-844 (2002).


583. SEEMAN, P., and KAPUR, S.: Antipsychotic affinity and occupancy at dopamine D2

receptors. Int. Congress Biol. Psychiat. (Berlin; 2000).


584.[380]. KAPUR, S., McCLELLAND, R.A, VANDERSPECK, S.C., WADENBERG, M.-L.G.,

BAKER, G., NOBREGA, J., ZIPURSKY, R., and SEEMAN, P.: Increasing D2 affinity

results in the loss of clozapine’s atypical antipsychotic action. Neuroreport 13(6): 831-835

(2002)


585.[381]. KAPUR, S., and SEEMAN, P.: Reply: Does Fast Dissociation From the Dopamine D2

Receptor Explain the Action of Atypical Antipsychotics?: - A New hypothesis. Am. J.

Psychiat. 159: 154-155 (2002).


586.[382]. SEEMAN, P. and KAPUR, S.: Results without regrets – Mechanism of Action of Atypical

Antipsychotics. Eur. College Neuropsychopharmacology, Istanbul, Oct. 14 (2001). 


587.[383]. SEEMAN, P. and MADRAS, B.K.: Methylphenidate elevates resting dopamine which lowers

impulse-triggered release of dopamine: a hypothesis. Behavioural Brain Res. 130: 79-83

(2002).


588.[384]. SEEMAN, P.: Atypical antipsychotics: Mechanism of action. Excerpta Medica Japan. (Oct.,

2001).


589. VANDERSPEK, S.C., NOBREGA, J., BROWNLEE, B.A, SEEMAN, P.., and KAPUR, S.:

Animal studies of antipsychotics use doses which are NOT representative of the clinical

condition - potential implications and suggested solutions. Biol. Psychiat. 51: 121S (2002).

Abstract.


590.[385]. SEEMAN, P.: Atypical Antipsychotics: Mechanism of Action. Can. J. Psychiat. 47: 27-38

(2002).


591.[386]. NOVAK, G., KIM, D., SEEMAN, P.., and TALLERICO, T.: Schizophrenia and Nogo:

elevated mRNA in frontal cortex and higher prevalence of a homozygous CAA insert

polymorphism. Molecular Brain Res. 107: 183-189 (2002).


592.[387]. SUN, W., GINOVART N, KO, F., SEEMAN, P.., and KAPUR, S.: In vivo evidence for

dopamine-mediated internalization of D2 receptors after amphetamine: Differential findings

with [3H]raclopride versus [3H]spiperone. Mol. Pharmacol 63: 456-462 (2003).


593.[388]. KAPUR, S., and SEEMAN, P.: Reply to Comment by J.H. Krystal and D.C. D’Souza on

“Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine

D2 receptor.” Biol. Psychiatry 50: 555 (2001).


594.[389]. KAPUR, S., and SEEMAN, P.: Atypical antipsychotics, cortical D2 receptors and sensitivity

to endogenous dopamine. Brit. J. Psychiat. 180: 465-466 (2002).


595.[390]. KO, F., SEEMAN, P., SUN, W.S., AND KAPUR, S.: Dopamine D2 receptors internalize in

their low-affinity state. Neuroreport 13(8, June): 1017-1020 (2002).


596.[391] SEEMAN, P., TALLERICO, T., KO, F., TENN, C. AND KAPUR, S.: Amphetamine-

sensitized animals show a marked increase in dopamine D2High receptors occupied by

endogenous dopamine – even in the absence of acute challenges. Synapse 46: 235-239 (2002).


597.[392] SEEMAN, P., TALLERICO, T.: Link between dopamine D1 and D2 receptors in rat and

human striatal tissues. Synapse 47: 250-254 (2003).


598.[393] SEEMAN, M.V., and SEEMAN, P.: Choosing an antipsychotic and why. Medscape, Wed.,

Sept. 18, 2002.


599. VANDERSPEK, S.C., BROWNLEE, B.A., NOBREGA, J., McCLELLAND, SEEMAN, P.,

KAPUR, S.: Converting a typical antipsychotic into an atypical one – the critical role of D2.

Schizophrenia Res. (2003). (Abstract)


600.[394] SEEMAN, P.: The Creation of Psychopharmacology, by David Healy, Harvard University

Press, Cambridge, MA, 2002, pp. 469. Nature Medicine, October 15, 2002. (Book Review).


601.[395] SEEMAN, P.: Atypical antipsychotics: Mechanism of action. Reply to Dr. J.H. Friedman.

Can. J. Psychiatry 48: 62-64 (2003).


602. KAPUR, S., and SEEMAN, P.: Hot paper in Essential Science Indicators: “Does Fast

Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical

Antipsychotics?: - A New hypothesis.” Am. J. Psychiat. 159: 154-155 (2002). ESI website,

November 2002.


603.[396] SEEMAN, P. , KO, F., and TALLERICO, T.: Dopamine receptor contribution to the action

of PCP, LSD, and ketamine psychotomimetics. Mol. Psychiatry 10: 877-883 (2005).


604.[397] CHUNG, C., TALLERICO, T., and SEEMAN, P.: Schizophrenia hippocampus has elevated

expression of chondrex glycoprotein gene. Synapse 50: 29-34 (2003).


605.[398] AGID, O., SEEMAN, P. and KAPUR, S.: The ‘delayed onset’ of antipsychotic action - an

idea whose time has come and gone. J. Psychiat. Neurosci. 31: 93-100 (2006).


606.[399] SEEMAN, P. , and KAPUR, S.: Anesthetics inhibit high-affinity states of dopamine D2 and

other G-linked receptors. Synapse 50: 35-40 (2003).


607. SEEMAN, P. , TALLERICO, T., and KAPUR, S.: The high-affinity state of the dopamine

D2 receptor in the action of amphetamine, anesthetics, and atypical antipsychotics. Canad.

College Neuropsychopharmacol. (Montreal, June 1, 2003). Abstract.


608.[400] SEEMAN, P. , TALLERICO, T., and KO, F.: Dopamine displaces [3H]domperidone from

high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in

isotonic medium: Implications for human positron emission tomography. Synapse 49; 209-

215 (2003).


609.[401] SEEMAN, P., and SEEMAN, M.V.: The dopamine hypothesis of schizophrenia. In:

Handbook of Medical Psychiatry, edited by J.C. Soares and S. Gershon, Marcel Dekker, New

York, 2003, pp. 259-266.


610.[402] SILVESTRI, S., NEGRETE, J.C., SEEMAN, M., SHAMMI, C.M., and SEEMAN, P.: Does

nicotine affect D2 receptor upregulation? A case-control study. (Acta Psychiatrica Scand.

109: 313-317 (2004).


611.[403] GEORGE, S.R., NG, G.Y.K., LEE, S.P., FAN, T., VARGHESE, G., WANG, C., DEBER,

C.M., SEEMAN, P., and O’DOWD, B.F.: Blockade of G protein-coupled receptors and the

dopamine transporter by a transmembrane domain peptide: Novel strategy for functional

inhibition of membrane proteins in vivo. J. Pharmacol. Exper. Therap. 307: 481-489 (2003).


612.[404] SEEMAN, P., TALLERICO, T., and KO, F.: Alcohol-withdrawn animals have a prolonged

increase in dopamine D2High receptors, reversed by general anesthesia: relation to relapse?

Synapse 52: 77-83 (2004).


613.[405]  SEEMAN, P., WEINSHENKER, D., QUIRION, R., SRIVASTAVA, L., BHARDWAJ, S.K.,

GRANDY, D.K., PREMONT, R., SOTNIKOVA, T., BOKSA, P., EL-GHUNDI, M.,

O’DOWD B.F., GEORGE S.R.,  PERREAULT, M.L., MANNISTO, P.T., ROBINSON, S.,

PALMITER, R.D., and TALLERICO, T.: Dopamine supersensitivity correlates with D2High

states, implying many paths to psychosis. Proc. Nat. Acad. Sci. U.S.A. 102: 3513-3518

(2005).


614.[406] SEEMAN, P.: Comment: Diverse psychotomimetics act through a common signaling

pathway. Science 305: 180 (2004).


616. SCHANK, J.R., COLE, C.D., LILES, L.C., SEEMAN, P., and WEINSHENKER, D.:

Dopamine beta-hydroxylase deficiency alters cocaine-induced locomotion and reward in

mice. Soc. Neurosci. Abstr. 30: (2004).


617.[407] SEEMAN, P., and SEEMAN, M.V.: Schizophrenia research in Canada, 1964-2004. In:

History of Canadian College of Neuropsychopharmacology, P. Hrdina and Y. Lapierre, eds.

(2005, in press).


618.[408] SEEMAN, P.: Atypical antipsychotics: Mechanism of action. Focus 2: 48-58 (2004).


619.[409] SCHANK, J.R., VENTURA, R., PUGLISI-ALLEGRA, S., ALCARO, A., COLE, C.D.,

LILES, L.C., SEEMAN, P., and WEINSHENKER, D.: Dopamine β-hydroxylase knockout

mice have alterations in dopamine signaling and are hypersensitive to cocaine.

Neuropsychopharmacology 31: 2221-2230 (2006).


620.[410]. SEEMAN, P., SCHWARZ, J., CHEN, J.-F., SZECHTMAN, H., PERREAULT, M.,

McKNIGHT, G.S., RODER, J.C., QUIRION, R., BOKSA, P., SRIVASTAVA, L.K.,

YANAI, K., WEINSHENKER, D.,  and SUMIYOSHI, T.,  Psychosis pathways converge via

D2High dopamine receptors. Synapse 60: 319-346 (2006).


621.[411]. REMINGTON, G., SEEMAN, P., SHAMMI, C., MANN, S., and KAPUR, S.: “Extended”

Antipsychotic Dosing. Rationale and pilot data. J. Clin. Psychopharmacol. 25: 611-613

(2005).


622. SEEMAN, P.: Convergence of multiple gene pathways to psychosis. Eur.

Neuropsychopharmacol. 15 (suppl. 3): S336 (2005). (Eur. Collegium Neuropsychopharmacol.

Abstracts, Amsterdam, Oct. 24, 2005.)


623.[412]. SEEMAN, P.: An update on fast-off-D2 Atypical Antipsychotics. Am. J. Psychiat. 162:

1984-1985 (2005).


625. SEEMAN, P.: Getting to the source of schizophrenia. Healthcare Quart. 8: 20 (2005).


626.[413]. SEEMAN, P.: Dopamine and Dopamine Receptors. In: The Neurotransmitter era in

Neuropsychopharmacology, edited by T. Ban and R.U. Udabe, Collegium Int.

Neuropsychopharmacologicum, Polemos press, pp. 79-94 (2006).


627.[414]. SUMIYOSHI, T., SEEMAN, P., UEHARA, T., ITOH, H., TSUNODA, M., and KURACHI,

M.: Increased proportion of high-affinity dopamine D2 receptors in rats with excitotoxic

damage of the entorhinal cortex, an animal model of schizophrenia. Mol. Brain Res. 140: 116-

119 (2005).


628.[415]. SEEMAN, P., and LASAGA, M.: Dopamine agonist action of phencyclidine. Synapse 58:

275-277 (2005).


629.[416]. SEEMAN, P., KO, F., WILLEIT, M., MCCORMICK, P., GINOVART, N.: Anti-Parkinson

concentrations of pramipexole and PHNO occupy dopamine D2High and D3High receptors.

Synapse 58: 122-128 (2005).


630.[417]. WILSON, A.A., McCORMICK, P., KAPUR, S., WILLEIT, M., GARCIA, A., HUSSEY, D.,

HOULE, S., SEEMAN, P., and GINOVART, N.: Radiosynthesis and evaluation of [11C]-(+)-

4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential

radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission

tomography. J. Med. Chem. 48:4153-4160 (2005). 

   

631.[418]. WILLEIT, M., GINOVART, N., KAPUR, S., HOULE, S., HUSSEY, D., SEEMAN, P., and

WILSON, A.A.: High-affinity states of human brain dopamine D2/3 receptors imaged by the

agonist [11C]-(+)-PHNO. Biol. Psychiat. 59: 389-394 (2006).


632.[419]. NOVAK, G., SEEMAN, P., and TALLERICO, T.: Increased expression of

calcium/calmodulin-dependent protein kinase IIβ in frontal cortex in schizophrenia and

depression. Synapse 59: 61-68 (2005).


633.[420] SEEMAN, P.: Dopamine receptors, schizophrenia and antipsychotics. Canad. J. Diagnosis,

Special edition pp. 1-7 (2006). 


634.[421]. VASDEV, N, SEEMAN, P., GARCIA, A., STABLEFORD, W.T., NOBREGA, J., HOULE,

S., and WILSON, A.A.: Syntheses and in vitro evaluation of fluorinated naphthoxazines as

dopamine D2/D3 receptor agonists; Radiosynthesis, ex vivo biodistribution and

autoradiography of [18F]F-PHNO congeners. Nucl. Med. Biol. 34(2): 195-203 (2007).


635. SUMIYOSHI, T., SEEMAN, P., UEHARA, T., ITOH, H., TSUNODA, M., and KURACHI,

M.: Increased proportion of high-affinity dopamine-D2 receptors in rats with excitotoxic

damage of the entorhinal cortex: A vulnerability animal model of schizophrenia. Soc.

Neurosci. Abstr. 31 (2005).


636.[422]. GINOVART, N., KAPUR, S., GALINEAU L., WILLEIT, M., MIZRAHI, R., SEEMAN, P.,

HOULE, S., and WILSON, A.A.: Binding characteristics and sensitivity to endogenous

dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of

D2-receptors in vivo using positron emission tomography. J. Neurochem. 97: 1089-1103

(2006).


637.[423]. VASDEV, N., NATESAN, S., GALINEAU, L., GARCIA, A., STABLEFORD, W.T.,

McCORMICK, P., SEEMAN, P., HOULE, S., and WILSON, AA: Radiosynthesis, in vivo  and ex vivo evaluation of carbon-11 labelled (S)-(–)propyl-3-(3-hydroxyphenyl)piperidine

([11C]Preclamol) as a partial dopamine D2 receptor agonist for PET. Synapse 60: 314-318

(2006).


638.[424]. SEEMAN, P.: In session with Philip Seeman. Role of dopamine in psychopharmacology.

Primary Psychiatry 13: 37-40 (2006).


639.[425]. SEEMAN, P.: Targeting the dopamine D2 receptor in schizophrenia. Expert Opinion on

Therapeutic Targets 10: 515-531 (2006).


640.[426]. SEEMAN, P., WILSON, A, GMEINER, P., and KAPUR, S.: Dopamine D2 and D3 receptors

in human putamen, caudate nucleus, and globus pallidus. Synapse 60: 205-211 (2006). 


641.[427]. KO, F., TALLERICO, T., and SEEMAN, P.: Antipsychotic pathway genes with expression

altered in opposite direction by antipsychotics and amphetamine. Synapse 60: 141-151

(2006).


642. VASDEV, N., SEEMAN, P., GARCIA, A., STABLEFORD W, HOULE S, and WILSON

AA: Syntheses and in vitro evaluation of fluorinated naphthoxazines as D2 agonists, and

radiosynthesis of [18F]FPHNO. Soc. Nucl. Med. abstr. (2006).


643.[428]. SEEMAN, P.: Dopamine receptors and antipsychotic drugs in health and disease. In Larry R.

Squire, Editor-in-Chief, Encyclopedia of Neuroscience, Academic press, Oxford, 2008, pages

……….,  (http://www.sciencedirect.com/science/articleB77C6-4B0FVKG50/2/a46e29f9e454d2d7bc5426791ce5f202


644.[429]. SEEMAN, P., KO, F., JACK, E., GREENSTEIN, R., and DEAN, B.: Consistent with

dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal

model of schizophrenia and in post-mortem schizophrenia brain. Synapse 61: 303-309 (2007).


645.[430. WOLINSKY, T., SWANSON, C.J., SMITH, K., ZHONG, H., BOROWSKY, B., SEEMAN,

P, BRANCHEK, T., and GERALD, C.P.: The Trace Amine receptor-1 knockout mouse: an

animal model with relevance to schizophrenia. Genes, Brain and Behaviour (2006). E-Pub

Dec. 21.


646.[431] GREENSTEIN R, NOVAK, G., and SEEMAN, P.: Amphetamine sensitization elevates

CaMKIIß mRNA. Synapse 61: 827-834 (2007).


647. McCORMICK, P.N., GINOVART, N., VASDEV, N., SEEMAN, P., KAPUR, S., and

WILSON, A.A.: Isoflurane increases both the specific binding ratio and sensitivity to

amphetamine challenge of [11C]-(+)-PHNO. Soc. Nucl. Med. Abstr. (2006).


648        SEEMAN, P.: Psychoses Converge via D2High Receptors. Eur. Neuropsychopharmacol. 16

(Suppl. 4): S191-S192 (2006).


649.  SAMAHA, A.-N., SEEMAN, P., and KAPUR, S.: Gradual and persistent loss of the

antipsychotic efficacy of chronic haloperidol: “Breakthrough” dopamine supersensitivity

during treatment. Soc. Neurosci. Abstr. 32 (2006).


650. SEEMAN, P.: Probing the biology of psychosis, schizophrenia and antipsychotics. Medscape

interview with Jessica Gould. Online (Aug. 2006).


651.[432].     SEEMAN, P., HALL, F.S.. and UHL, G.: Increased dopamine D2High receptors in knockouts

of the dopamine transporter and the vesicular monoamine transporter may contribute to

spontaneous hyperactivity and dopamine supersensitivity Synapse 61: 573-576 (2007).


652.[433].     WILLEIT, M., GINOVART N., GRAFF, A., RUSJAN, P., VITCU, I., HOULE, S.,

SEEMAN, P., WILSON, A.A., and KAPUR, S.: First human evidence of d-amphetamine

induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission

tomography study. Neuropsychopharmacology (2007, epub Apr. 4).


653.[434].     SEEMAN, P., McCORMICK, P., and KAPUR, S.: Increased dopamine D2High receptors in

amphetamine-sensitized rats, measured by the agonist [3H](+)PHNO. Synapse 61: 263-267

(2007).


654.[435]. SEEMAN, P.: Anti-Parkinson therapeutic potencies correlate with their affinities for

dopamine D2High receptors. Synapse 61: 1013-1018 (2007).


655.[436].     SEEMAN, P., CARUSO, C., M. LASAGA: Memantine agonist action at dopamine D2High

receptors. Synapse 62: 149-153 (2008).


656. SAMAHA, A.-N., SEEMAN, P., STEWART, J., RAJABI, H., and KAPUR, S.: Chronic

haloperidol gradually and persistently loses its antipsychotic efficacy over time: Pre- and

post-synaptic changes in dopamine function during treatment. Int. Congr. Schizophrenia

(2007) Abstract.


657.[437].  SHUTO, T., SEEMAN, P., KUROIWA, M., NISHI, A.: Repeated administration of a

dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High

and D2High reeptors in methamphetamine-sensitized rats. Eur. Neuropsychopharmacol. (2008,

in press).


658.[438]. GRAFF-GUERRO, A., WILLEIT, M., GINOVART, N., MAMO, D., MIZRAHI, R.,

RUSJAN, P., VITCU, I., SEEMAN, P., WILSON, A.A., and KAPUR, S.: Brain region

binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy

humans. Human Brain Mapping 29(4): 400-410 (2008).


659.[439]. SEEMAN, P., and GUAN, H.-C.: Dopamine partial agonist action of (-)OSU6162 is

consistent with dopamine hyperactivity in psychosis. Eur. J. Pharmacol. 557: 151-153 (2007).


660.[440]. TASSIN, J.-P., TORRENS, Y., SALOMON, L., LANTERI, C., and SEEMAN, P.: Elevated

dopamine D2High receptors in alpha-1beta-adrenoceptor knockout supersensitive mice.

Synapse 61: 569-572 (2007).


661.[441]. SEEMAN, P. , CARUSO, C., and LASAGA, M.: Dopamine partial agonist actions of the

glutamate receptor agonists LY 354,740 and LY 379,268. Synapse 62: 154-158 (2008).


662.[442]. PERREAULT, M.L, SEEMAN, P. and SZECHTMAN, H.: Kappa-opioid receptor

stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization

model of obsessive-compulsive disorder (OCD). Behav. Neurosci. 121: 976-991 (2007). 


663.[443]. SAMAHA, A.-N., SEEMAN, P., STEWART, J., RAJABI, H., and KAPUR, S.:

“Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to

failure over time. J. Neurosci. 27: 2979-2986 (2007).


664. SEEMAN, P.: Comments on the publication of Zhao et al. Schizophrenia Res. Forum.

http://www.schizophreniaforum.org/new/detailprint.asp?id=1304


666.        BYMASTER, F., & SEEMAN, P.: Pre-clinical pharmacology of olanzapine. (Unpublished).


667.[444]. SEEMAN, P.: Dopamine D2High receptors moderately elevated by sertindole. Synapse 62:

389-393 (2008).


668.[445]. McCORMICK, P.N., KAPUR, S., SEEMAN, P., and WILSON, A.A.: Dopamine D2

receptor radiotracers, [11C]-(+)-PHNO and [3H]-raclopride, are indistinguishably inhibited by

D2 agonists or antagonists ex vivo. Nucl. Med. Biol. 35: 11-17 (2008). Epub 2007 Nov 19.


670. SAMAHA, A.-N., RECKLESS, G.E., SEEMAN, P., and KAPUR, S.: Continuous but not

intermittent haloperidol treatment leads to dopamine supersensitivity and a progressive loss in

antipsychotic efficacy. “50 Years of dopamine”. Gotenberg, Sweden (2007). Abstract. 


671.[446].  SEEMAN, P.: Dopamine and Schizophrenia. Scholarpedia, 2(10):3634 (2007).


672. SAMAHA, A.-N., RECKLESS, G.E., SEEMAN, P., and KAPUR, S.: Maintaining

continuous but not transient therapeutic brain levels of antipsychotic leads to dopamine

supersensitivity and an enduring loss of antipsychotic efficacy. Soc. Neurosci. Abstr. (2007). 


673. SHUTO, T., KUROIWA, SEEMAN, P., and NISHI, A.: Repeated administration of

dopamine D1 receptor agonist reverses the increased proportion of high-affinity dopamine D1

and D2 receptors in methamphetamine-sensitized rats. Soc. Neurosci. Abstr. (2007).


674.[447]. SEEMAN, P.: All psychotic roads lead to increased D2High dopamine receptors. A

perspective. Clin. Schizophrenia and Related Psychoses Jan., 2008: 351-355.


675.[448]. SIMOLA, N., MORELLI, M., and SEEMAN, P.: Increase of dopamine D2High receptors in

the striatum of rats sensitized to caffeine motor effects. Synapse 62: 394-397 (2008).


676.[449] SEEMAN, P.: Dopamine D2High receptors on intact cells. Synapse 62: 314-318 (2008).


677.[450]. BRIAND, L.A., FLAGEL, S.B, SEEMAN, P., ROBINSON, T.E.: Cocaine self-

administration produces a persistent increase in dopamine D2High receptors. Eur. J.

Neuropsychopharmacol. (2008) Epub Feb. 18, 2008. 


679.[452].  SEEMAN, P.: Dopamine D2High receptors moderately elevated by bifeprunox and

aripiprazole. Synapse (2008, in press).


681.[454]. SEEMAN, P.: Dopamine D2High receptors measured ex vivo are elevated in amphetamine-

sensitized animals. Synapse (2008).


682.[455]. SEEMAN, P: Glutamate agonists for schizophrenia stimulate dopamine D2High receptors

Schizophrenia Res. 99 (1-3): 373-374 (2008). E-pub Dec. 10, 2007.


683.[456]. SEEMAN, P.: Historical Introduction to The Dopamine Receptors. In: The Dopamine

Receptors, edited by K. Neve, Humana Press (2008, in press).


684. KING, M., SEEMAN, P., MARSDEN, C. FONE, K.C.F.: Increased dopamine D2High

receptors in rats reared in social isolation, an animal model of schizophrenia. Brit. Pharmacol.

Soc. (2007), abstract.


685.[457]. SAMAHA, A.-N., RECKLESS, G., SEEMAN, P., DIWAN, M., NOBREGA, J.N., KAPUR,

S.: Less is More: Antipsychotic drug effects are greater with transient rather than continuous

delivery. Biol. Psychiatry (2008, in press). Epub Feb 22, 2008.


686. SEEMAN, P.: Comments on Minnesota Consensus Group document (A. MacDonald et al.)

on What we Know…What we don’t know about schizophrenia.

http://www.schizophreniaforum.org/whatweknow/newssearch.asp?categoryID=24&type=all

   

687.[458]. KING, M.V., SEEMAN, P., MARSDEN, C.A., FONE, K.C.F.: Increased dopamine D2High

receptors in rats reared in social isolation. (Submitted for publication, 2008).